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List of abbreviations 
ACE Angiotensin converting enzyme 
ACoA Arteria comiinuiiicans anterior 
ADH Antidiuretic hormone, Vasopressin 
ANP Atrial natriuretic peptide 
AQP Aquaporin 
BNP B-typ natriiirctic peptide 
C Cr Creatinine clearance 
C El Electrolyte clearance 
c H2O Solute free water clearance 
C K+ Potassium clearance 
C_Na+ Sodium clearance 
C O s m Osmotically active substances clearance 
cAMP 3', 5'-cyclic adenosine monophosphate 
cDI Central diabetes insipidus 
CNP C-type natriuretic peptide 
CNS Central nervous system 
CPM Central pontine myelinolysis 
CSW Cerebral salt wasting 
CT Computed tomography 
CVP Central venous pressure 
DDAVP Desmopressin, 1 -desamino-8-D-argininc-vasopressin 
DI Diabetes insipidus 
DNP D-type natriuretic peptide 
dU K+ Daily urine output of potassium 
dU Na+ Daily urine output of sodium 
ECF Extracellular fluid 
EPM Extrapontine myelinolysis 
EWC Electrolyte free water clearance 
FE H 2 0 Excretion fraction of free water 
FE K+ Excretion fraction of potassium 
FE_Na+ Excretion fraction of sodium 
FE Osm Excretion fraction of osmotically active substances 
GCS . Glasgow Coma Scale 
GFR Glomerular filtration rate 
GOS Glasgow Outcome Scale 
HC03- Hydrogencarbonate (bicarbonate) 
ICF Intracellular fluid 
TCP Intracranial pressure 
ICH Intracerebral haemorrhage 
IS Ischemic stroke 
ISF Interstitial fluid 
TVF Intravascular fluid 
NNTCU Neurologic-neurosurgical intensive care unit 
non cDI Hypcrnatracmia non central diabetes insipidus 
NP Natriuretic peptide 
NT-proBNP N-terminal proB-type natriuretic peptide 
NYHA New York Heart Association 
RAAS Renin-angiotensin-aldosterone system 
S Alb Serum albumin 
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S Ca2+ Scrum calcium 
S Cl- Seriun chloride 
S Cr Serum creatinine 
S Glu Serum glucose 
S K+ Serum potassium 
S Mg2+ Serum magnesium 
S_Na+ Serum sodium 
SOsm Scrum osmolality 
S OsmE Serum osmolality effective 
S OsmC Serum osmolality calculated 
SAH Subarachnoid haemorrhage 
SI ADII Syndrome of inappropriate secretion of antidiuretic hormone 
Sp gr Specific gravity of urine 
TBI Trauma brain injury 
TBW Total body water 
U Osm Urine osmolality 
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Introduction 
Dysbalances of effective osmolality are some of the most frequent and serious 
complications in neurointensive carc. Their severity lies in brain oedema in hyponatremia and 
dehydration of the brain in hypernatraemia [1-8]. in brain diseases there are three typical 
syndromes: Hyponatraem ia involves two syndromes arising from different causes. The first is 
depletion hyponatraemia induced by natriuresis in cerebral salt wasting (CSW) syndrome, the 
second is dilutional hyponatraemia through water retention in syndrome of inappropriate 
secretion of antidiuretic hormone (SIADH), [3, 7, 9], Hypernatraemia is brought about by water 
diuresis in central diabetes insipidus (cDl), [2, 8], Due to the seriousness of dysnatraemia in 
acute brain diseases, timely and accurate diagnosis is necessary. Nowadays this is easily 
achieved through measuring and calculating renai function parameters [10-18]. 
Theory 
Osmolality 
Osmolality is given by the overall number of soluble particles in 1 kg of fluid regardless 
of their size or electrical charge. The most important soluble substances are ions, others include 
glucose, urea and proteins. The main part of water extent in the organism (total body water, 
TBW) is made up from intracellular fluid (ICF) and extracellular fluid (EOF), which is divided 
into intravasal (IVF) and interstitial fluids (ISF). Osmolality of these water extents is given by a 
different type of soluble particles. The differing distribution of ion concentration between ICF 
and ECF is the result of the presence of a semipermeable membrane between them, enabling the 
free flow of small ions and molecules according to Donan's balance as well as other activities of 
ion pumps in cell membranes. In ECF, overall osmolality is largely caused by sodium and its 
responding anions, less by glucose arid urea and finally by plasma proteins. Ion composition in 
TVF and ISF is nearly the same. TSF is ultrafiltrate blood plasma with minimal proteins which 
leads to a difference in concentration of ions according to Gibbs and Donnan's balance, to 
maintain electronic neutrality. This means that in ISF there are more anions. In ICF the main 
osmotic particles are potassium and magnesium from cations, and protein and phosphates from 
anions. 
Osmolality between individual spaces is kept in balance, meaning that whenever a change 
in osmolality occurs in a certain space, the newly arisen osmotic gradient is subsequently 
levelled. The principal is based on the permeability of the membranes between individual 
compartments of bodily fluids. Only water and urea can flow through them freely, other solutes 
are limited. Cell membranes separate ICF from TSF, while capillary walls separate ISF from IVF 
[12, 3, 19, 20]. 
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Effective osmolality 
Effective osmolality is caused by particles which do not flow freely but are distributed in 
some of the aforementioned bodily fluids. During their accumulation hypertonicity arises, and 
then water flows through the membrane and balances the osmotic gradient. Tt is therefore evident 
that only effective osmolality and not overall osmolality can induce the shift in water. Sodium 
and glucose participate in effective osmolality of ECF, whereas urea, which flows freely, does 
not. The main ion of ECF is sodium, thus its concentration has the biggest influence on effective 
osmolality of ECF. Hypernatraemia causes hypertonicity of ECF, and the following shift leads to 
dehydration of cells. On the other hand, hyponatraemia gives rise to cell oedema. In some cases, 
hyponatraemia is not connected to low effective osmolality, for example during osmotherapy by 
mannitol or hyperglycaemia (an increase of 5,5 rnmol/1 in glycemia lowers sodium by 1,5 
mmol), [12, 13]. 
Regulation of osmolality 
Plasma osmolality in the organism is maintained in the narrow range 275 - 295 uimol/kg 
[12]. Regulation is controlled from the brain by osmoreceptors in the hypotalamus, which make 
up the functional osmoreceptor complex. Intake of fluids due to a feeling of thirst and the 
amount of diuresis due to antidiuretic hormone (ADH) are influenced by serum osmolality 
changes. During an increase in serum osmolality, thirst and ADH rise, while the opposite occurs 
during a decrease. 
ADH is a nanopeptide, synthesised in neurons in the area of the nucleus supraopticus and 
paraventricularis in the hypothalamus. From here it is transported with neurofysin to storage 
granules in pars nervosa of the neurohypophysis. After stimulation, it is released into the blood 
stream [21]. Reference levels are up to 4 pg/ml, after stimulation they rise to 10 pg/ml. The 
maximum effective urine osmolality is at the level of 20 pg/ml. Its plasma halt-life is very short, 
just 10 to 35 minutes [22]. 
ADH influences reabsorbtion of water in the kidneys through the V 2 receptors. This 
antidiuretic effect was described 10 years later than its vasoprcsoric effect, by Farini and von 
Veldeti in 1913. These tubular cells are relatively impermeable to water, so urine cannot 
concentrate in the absence of ADH. Water is transported through the membranes of epithelial 
cells by water channels - aquaporines (AQP). After connccting the hormone to specific V 2 
receptors, intracellular 3',5'- cyclic adenosine monophosphate (cAMP) takes place, stimulating 
the insertion of aquaporine 2 (AQP 2) into the apical membraue and thus raising its water 
permeability [15, 21, 22], 
ADH is not only released during raised serum osmolality, but also with other signals, i.e. 
nonosruolal stimulation. This occurs in hypovolemia (a 10 - 20 % volume decrease) and 
hypotension (a 10 % drop in blood pressure) induced by carotic and aortal baroreceptors and 
atrial volume receptors in the heart. Maximum secretion is reached during a 30 % fell in blood 
pressure. The vasoconstrictive effect of ADH is caused by the V 1 receptor in the cell wall, as 
described by Oliver and Schafer in 1895 before the antidiuretic effect was found, which is why 
its original name was vasopressin [20, 22]. Other stimuli include pain, nausea, hypoxia, 
pharyngeal stimulation and further endogenic and exogenic particles. 
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Measuring and calculating osmolality 
Osmolality can be measured using the cryoscopic method on the osmometre. The point of 
a solution's solidification is proportionate to the amount of osmotically active particles. A unit is 
mmol/kg H2O. 
It is also possible to estimate osmolality by calculating the main osmotically active 
plasma components. There is a wide variety of formulae, but the most accessible and reliable is 
considered to be Kazda and Hendl's following equation, which was the result of comparing 
thirteen formulae with measured osmolality [23]: 
P_Osmcaicuk(ed = 2*P_Na+ + P Glucose + P Urea 
The difference between measured and calculated osmolality is known as the osmolal gap. 
Normal values are up to 10 mmol/kg, larger differences can be due to small molecular particles, 
which are not included in the formula [12, 15]. In neurointensive care the osmolal gap has a 
bearing on osmotherapy with mannitol [24]. 
Sodium 
Sodium is the main extracellular cation, and therefore the most important in EOF 
osmolality. 50 % of the total amount of sodium in the body (approximately 4000 mmol) is found 
in ECF, 40 % in bone tissue and 10 % in ICF. Serum reference levels are between 135 - 143 
mmol/1, with 120 - 240 mmol/day in urine. Around 22 400 mmol are filtered daily in the 
glomeniles, 99 % of which is reabsorbed and only 1 % is excreted in urine [22]. Sodium 
excretion is regulated by several mechanisms in the kidneys. 
Regulation of sodium in the organism 
Sodium reabsorbtion in the tnbules is influenced by the mineralocoiticoid aldosterone, a 
steroid hormone from the adrenal cortex. Its production is controlled by renin from the 
juxtaglomerular apparatus of the kidneys. Renin secretion increases when blood pressure 
decreaeses, which leads to low pressure in the vasa afferent, and also during low concentration of 
sodium in the macula densa of the kidney. Renin turns angiotensinogeii to angiotensin I, which 
goes on to become angiotensin II (through the angiotensin converting enzyme - ACE), and then 
III. This system is called renin-angiotensin-aldosterone (RAAS). Aldosterone raises sodium 
reabsorbtion and therefore water in the kidney's distal tubule. At the same time, it increases 
potassium excretion. The purpose of this regulation is to increase volume circulation and blood 
pressure through the vasoconstricter effect of angiotensin II. and III. This way of increasing 
aldosterone is known as secondary hyperaldostcronisin, in contrast to primary 
hyperaldosteronism, which is caused by adenoma. In the urine there is a sodium-to-potassium 
concentration rate lower than 1. Hypoaldosteronism occurs during insufficiency in (he adrenal 
gland. There is increased loss of sodium and reabsorbtion of potassium. In pharmacology, 
spiralactone is the antagonist of aldosterone, and fludrocortisone is a substance with mineral 
corticoid effect. 
Further natriuretic regulation mechanism are natriuretic peptides (NP), which have the 
opposite effect to aldosterone. They cause diuresis and natrinresis, vasodilatation and inhibit the 
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RAAS. NP are a family of structurally similar peptides - Atrial natriuretic peptide (ANP), B-
type natriuretic peptide (BNP, brain natriuretic peptide), C-type natriuretic peptide (CNP) 
originating in the central nervous system and vascular tissues and D-type natriuretic peptide 
(DNP), which was isolated from the venom of the Green Mamba (Dendroaspis Angusticeps), 
[25-28], 
The first NP to be described was ANP, which was seperated from atrium by de Bold in 
1981 [29]. Later, in 1988, BNP was isolated from porcine brain tissue [30]. Even though it was 
first discovered in the brain, nowadays we know that it is mainly produced in the cardiac 
ventricular myocytes. The main stimulus for its synthesis and secretion is cardiac wall stretch 
[25, 27]. The natriuretic effect of ANP and BNP lies in increasing glomerular filtration, the 
direct effect in collecting tubule and suppression the RAAS [28]. Their synergy is assumed, BNP 
raises water and sodium to the collecting tubule, while ANP inhibits the reabsorbtion of sodium. 
Both hormones are synthesized in tissues from preprohormones (151-amIno-acid pre-proANP, 
132-amino-acid pre-proBNP), which are processed into prohormones (126-amino-acid proANP, 
108-amino-acid proBNP). Shortly before release into circulation, C-terminal biologically active 
hormone ANP (28-amino-acid) and BNP (32-amino-acid), taking effect in the target tissues 
through specific receptors, are separated. The remaining parts also go into circulation and are 
known as N-terminal fragments. Both active hormones have a shorter half-life (ANP 3 minutes, 
BNP 21 minutes) than their N-terminal fragments. At present assessment of active and N-
terminal parts is available. In clinical practice BNP and N-terminal pro B-type natriuretic peptide 
(NT-proBNP) are used. From the diagnostic point of view both methods are comparable, but in 
routine practice NT-proBNP is more suitable owing to its longer biological half-life [25,27]. 
NT-proBNP is typically used in cardiology as a biochemical marker of heart failure due 
to left ventricular systolic dysfunction [31, 32]. However, elevated levels of ANP and BNP are 
also reported in hyponatremia with natriuresis in acute brain diseases - Cerebral Salt Wasting 
(CSW) syndrome. This condition occurs very often in cases of subarachnoid haemorrhage 
(SAH), [33-36], A relationship has been found between increased levels of BNP and 
symptomatic cerebral vasospasm [35]. Elevated BNP has also been found in intracranial 
hypertension [34], Recently BNP assessment has been publicised in regard to further brain 
diseases: Sviri described increased levels in acute trauma brain injury [37] and Jensen has 
focused on observing NT-proBNP as a prognostic marker in acute ischemic stroke [38], 
Further natriuretic regulation mechanisms are part of Urodilatin, produced in distal 
tubules, and a Digitalis-like hormone from the adrenal gland which causes natriuresis by 
inhibiting Na+K+-ATPase. 
The influence of diuretics on serum sodium 
Loop diuretics lower iont reabsorbtions in the Henle asccnding loop and distal tubule, 
which leads to sodium secretion in tubule and currently they influence osmotic gradient. 
Through this mechanism more water than sodium is lost, causing hypernatraemia. Furosemide 
belongs to this group. 
Thiazides diuretics, on the other hand, cause hyponatraemia, because more sodium than 
water is lost as a result of interrupting the dilution capabilities of the distal and collecting 
tubules. Hydrochlorothiazide is an example of this group. 
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Renal function parameters 
Glomerular filtration rate 
Primary urine from passing blood arises in the first functional part of the nephron, or 
glomerulus as it is known. Only low-molecular particles can filter through the glomerulus, larger 
molecules do not get into primary urine. Low-molecular particles, which freely filter through the 
glomerulus and do not'turn into tubules (no secretion, reabsorbtion) are ideal for calculating 
glomelular filtration. Formula: 
GFR = U * V / P 
U - substance concentration in definite urine, V — volume of definite urine, P - substance 
concentration in plasma. 
This substance is inulin, but is not used in practice dne to its numerous disadvantages. 
Glomerular filtration is estimated according to clearance of endogenous creatinine. Although it is 
not ideal because creatinine is partly eliminated through tubular secretion, it is nonetheless very 
useful in clinical practice. The reference range is 1,3-2,8 ml/s (calculated to ideal body surface 
1,73 m2) 
Tubular function 
In the tubular part of the nephron, primary urine turns into definitive urine through 
reabsorbtion and secretion. Tubular reabsorbtion means the proportion from the original filtered 
amount in the glomerulus which is reabsorbed. Fraction excretion denotes the proportion from 
the original filtered amount in the glomerulus, which is eliminated into definitive urine. The 
formula for calculating substance fraction excretion: 
FE_X = U_X / P_X * P C r / U C r 
For this formula concentration of the observed substance in urine (U_X) and plasma (P_X) and 
concentration of creatinine in plasma (P_Cr) are necessary. The advantage of this parameter is 
that urine collection is not needed. In clinical practice, the following are used: excretion fraction 
of free water (FE_H20), excretion fraction of osmotically active substances (FEOsm), excretion 
fraction of sodium (FE Na4), excretion fraction of potassium (FE_K+). The reference range for 
these individual parameters can be seen in table 1. During a decrease in glomerulus filtration the 
values of all four FE rise. This is the kidneys' compensatory mechanism, with the aim of 
maintaining sufficient diuresis even as glomerular filtration falls. 
Table 1. Reference range of excretion fraction of: free water ( F E H 2 0 ) , 
osmotically active substanccs (FE_Osm), sodium (FE_Na+), potassium 
(FE_K+). 
fcífarfietěř : í l t icřcnce řaiiRC 
FE H 2 0 0,01 - 0 , 0 2 
FE Osm < 0,035 
FE Na* 0,004 - 0,012 
FE_K+ 0 ,04-0 ,19 
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Clearance of osmotically active substances, electrolyte; sodium, solute free water and 
clcctrolyte free water 
Clearance informs us of the amount of plasma which is completely purified of a certain 
substance during blood-flow through the kidneys for a period of time. These calculation 
parameters enhance the observation of renal functions. 
Clearance of osmotically active substances (COsffi, ml/s) denotes the amount of plasma 
purified from all active osmotic substances. 
C Osm = V * UOsm / P_Osm 
U_Osm - urine osmolality, P_Osm - plasma - serum osmolality, V - volume of definite urine 
(ml/s). This clearance is raised by hypercatabolic states with overproduction of urea, in diabetes 
mellihis or mannitol osmotherapy during overflow of osmotic diuresis. 
Electrolyte clearance (C_E1, ml/s) tells us of clearance of the main effective osmoles. There are 
different formulae according to calculated parameters. In the basic calculation there are only 
cation, sodium and potassium (1), more detailed formulae have their accompanying anions (2), 
while the most complex include glucose, mannitol and others (3). 
1) C_E1 = V* (U_Na+ + UJC*) / (P_ Na+ + PJK4), 
2) C_E1 = V* 2(U_Na+ + U j C ) /2(P_Na+ + PJC4), 
3) C_E1 = V* [2{U_Na++ U j O + UOther] / [2(P_ Na+ + PJC4) + P_Other], 
U_Na+ + U_K+ + U_Other - urine concentration of cations, sodium, potassium, others effective 
solutes, P_Na+ + P_K+ + U Other - plasma sodium, potassium, others effective solutes, V -
volume of definite urine (ml/s). Factor 2 includes accompanying anions. Formula 2 can be used 
when cation sodium and potassium along with their accompanying anions are the main 
extracellular effective solutes, meaning there is no hyperglycaeinia with glycosuria and mannitol 
is not given. 
Sodium clearance (C_Na+, ml/s) relates to the main extracellular cation - sodium. 
C Na4 = V * U Na+ / P J I a + 
Solute free water clearance (C_H20, ml/s) informs us of the reabsorbtion of active particles in 
the distal part of nephron, ft indicates in ml the amount of water which we would have to remove 
from hypertonic urine in order to adjust it to the level of plasma osmolality. 
C_H 2 0=V-C_0sm 
C_H20 = V - V * U Osm /P Osm 
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The formula calculates ail serum and urine osmolality. In low urine osmolality (hypotonic urine) 
its level is positive, whereas in high osmolality urine (hypertonic urine) it is negative. 
Electrolyte free water clearance (EWC, ml/s) relates lo effective osmolality. The EWC 
formula is derived from electrolyte clearance. 
EWC = V — C El 
EWC = V - V* 2(U_N^+ + U_K*) / 2(P_Na+ + PJC*) 
EWC = V - V* [2(U_Na++U K4) + U Other] / [2(P_ Na+ + P K 4 ) + P Other] 
A raised level of EWC means that the kidneys are eliminating more water than effective 
osmotic solutes, which leads to hypertonicity ECF. A fall in EWC on the other hand results in 
lower elimination of water by the kidneys and a low concentration of effective solutes in ECF. 
EWC and C El arc relatively new formulae, and are known as "second level" markers. 
They improve evaluation of effective osmolality dysbalances [18], 
CJT20 and EWC enable us to assess concentration efficiency of the kidneys. EWC 
relates to effective osmolality, unlike C_H20, which contains all osmolality including urea, so 
only EWC uses assessment of axis ADH-kidney disorders. Values of CJ320 and EWC 
parameters are mostly parallel, although not in all situations, for example when kidneys 
eliminate more urea and save ions, C_H20 will be negative and EWC positive. Table 2 shows 
the reference range for these clearances [11, 18]. 
During a drop in glomerular filtration C Osm, C_E1 and C Na+ fall while C_II20 rises. 
The dynamic for this change is due to alterations in glomerular filtration. This is in contrast to 
EWC, where practically the same values were discovered for moderately and steeply declining 
glomerular filtration (the only significant changes were from EWC to physiological GER.), [18]. 
Table 2. Reference range of clearance: osmotically active substances {C_Osm); 
electrolyte (C_EI), sodium (C Ni 1 ) , solute free water (C_H20) and electrolyte free water 
(EWC). 
Parameter Slídker 19?4 .lajbrtr 1997 
C Osm 0,066 ±0 ,017 0,0'H t 0,012 
C El 0,018 ±0,006 0,021 ±0,007 
C Na' 0,013 ±0 ,004 0,018±0,007 
C H j O -0,049 ±0 ,017 -0,018 ±0,011 
EWC -0,000 ±0,006 0,002 ±0,008 
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Evaluation of disorders of water aud ion metabolisms due to renal function parameters 
Assessment of axis ADH-kidneys through EWC parameters was worked out by Shoker in 
1994 [11], This is an evaluation of adequate secretion of ADH and kidney responses during 
serum osmolality changes. Shoker's evaluation of concentration efficiency: 
Hypoosmolality, hypotonicity - serum osmolality < 280 mmol/kg 
EWC >0,116 ml/s (101/day) normal response ADH-kidneys 
EWC 0,006-0,116 ml/s impaired response ADH-kidneys 
EWC < 0,006 ml/s (0,5 1/day) abnormal response ADT-T-kidneys 
Hyperosmolality, hypertonicity - serum osmolality > 295 mmol/kg 
EWC <0,005 ml/s (0,4 I/day) normal response ADH-kidncys 
EWC > 0,005 ml/s abnormal response ADH-kidneys 
Shoker used another parameter, C_Na+. He did not include cither a calculated sodium 
deposit (only a clinical estimate) or FE_Na+. 
These two parameters were added by Jabor in 1997. He used the Siggaard-Andersen 
model for extracellular and intracellular space for calculating sodium deposit. Extracellular space 
arises from serum sodium and an estimate of water volume of ECF. At the same time he inserted 
C_Ná+ and FE_Na+ into the algorithm [16, 17]. 
Effective osmolality disorders in acute brain diseases 
Dysnahaemia is one of the more frequent and serious dysbalances of effective osmolality 
in acute primary brain damage [1-8]. Hyponatremia is more common than hypernatraemia, 
which is however prognostically worse [1 ]. 
Three typical syndromes are known in brain diseases (table 3 and 4). Two are in 
hyponatraemia, and one is in hypernatraemia, Antidiuretic hormone causes all types of 
dysnatraemia. During an abundance of ADH hyponatraemia arises from water retention in the 
kidney. When ADH is insufficient water diuresis occurs, leading to hypernatraemia and cDT. 
Table 3. Typical syndromes of dysnatraemia in acute brain diseases. 
- AIÍIÍ | NÍ' 
Hyponatraemia SI ADH CSW 
Hypernatraemia cDI J 
Table 4. Differential diagnostics of CSW, STADH and cDT. 
• Parameter :; . CSW SIADH c p j 
S Na+ mmol/1 < 135 > 145 
SjOsm mmol/kg <280 >295 
Diuresis N | | NJ . R 
U Na+ mmol/1 > 2 5 < 2 5 
dU Na+ mmo l/day >150 | 1 0 0 - 1 5 0 < intake o fNa + 
U Osm/S Osm > 1 < 1 
U Osm/S Osm > l < 1 
C Cr ml/s N Í N 
C El ml/s Í N N 
BWC ml/s N I t 
FE Na+ t NJ . N F 
FE_H,0 Í N J T 
ADH N t I 
NP f N N J 
Renin,aldosterone t N N t 
N - normal, J. - decreased, | — increased. In SIADH it is necessary to dismiss: 
hypovolemia, hypotension, oedema, renal failure, hypothyreosis, hypocorticalism. 
Hyponatraemia in ncutc brain diseases 
Hyponatraemia is one of the more frequent dysbalances of effective osmolality in acute 
brain diseases [4, 5]. Tn subarachnoid haemorrhage it occurs in about 30-40% of patients [1, 7, 
39, 40]. It can also be found in other brain diseases: tumours, especially in pituitary adenoma 
[41-43], brain abscess, bacterial meningitis (36 - 58 %), hydrocephalus and trauma brain injury 
(TBI), [3]. Hyponatraemia always means serious complications in neurointensive care. It is 
linked to higher morbity and mortality [44]. Its severity is due to the onset of brain oedema. 
Acute hyponatraemia leads to significantly higher volume in trauma contusions in animal models 
[45]. Unlerberg et al [46] gave hyponatraemia as a cause of refractor intracranial hypertension in 
patients with TBI. Wijdicks [47] observed the relationship between hyponatraemia and the onset 
of ischemia in SAH. He found a significantly higher incidence in patients with hyponatraemia. 
Hyponatraemia in acute brain disease was first described by Peters in 1950 [48]. 
Nowadays it is most often connected with two syndromes, which arise on the basis of entirely 
different causes. These are depletive hyponatraemia, brought about by loss of sodium through 
urine (natriuresis) in cerebral salt wasting (CSW) syndrome and dilution hyponatraemia, which 
arises during retention of free water in syndrome of inappropriate secretion of antidiuretic 
hormone (SIADH). The first syndrome described in literature was CSW, by Peters (1950) and 
Cort (1954), [48, 49], Later, in 1957, Schwartz [50] introduced SIADH. Differential diagnostics 
for these two syndromes is impossible by means of basic laboratory parameters, because they are 
the same [8]. However, this can be achieved by using renal function parameters, which were first 
evaluated for this purpose in the 1990s, [10, 11]. Lolin & Jackowski [10] used the first calculated 
indicators C_Osm, C_H20, FE_Na+ and FE_H20 in 1992. Later, the so-called "second row" 
indicators were added - C El, EWC, C_Na\ From these parameters, axis ADH-kidneys 
dysbalances can be better evaluated by EWC [18], Tn CSW, when natriuresis is present, there is 
raised daily urine output of sodium (dU N a \ C_Osm, C_E1, C_Na+, FE_Na+ and FE_H20. 
Negative EWC is characteristic for SIADI-I regarding retention of free water. Differential 
diagnostics of these syndromes is both simple and easily accessible in clinical practice using 
these parameters. This is in contrast to assessment of the hormones which induce these 
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syndromes, ADH in STADII and NP in CWS, which is inaccessible in everyday clinical practice 
[8]. The significance of their measurement decreases with the development of compensatory 
mechanisms, which arise due to fluid volume changes and lead to secondary secretion of 
hormones. In SIADH, retention of free water causes volume expansion and further stimulation of 
NP. Tn CSW it is the other way round, primary elevation ofNP leads to volume depletion and a 
secondary increase in levels of ADH [9, 51]. 
Adding renal function parameters to differential diagnostics of both syndromes 
contributes to their timely diagnosis. Results from further studies have shown that in patients 
with acute brain disease CSW is more common than SIADH. Incidence of CSW is linked to 
primary brain disease, The most common is found in SAH, but also occurs in other lesions, for 
example TBI, glioms and meningitis [7, 52]. This is in contrast to STADH, which is found not 
only in primary brain lesions but also in various illnesses, tumours, lung diseases, drugs and 
others [15]. 
Owing to the various mechanisms of the onset of hyponatraemia, entirely different 
therapy is needed. In SIADH, this means fluid restrictions and the application of loop diuretics. 
There are two antagonists of ADH in the kidney, demeclocycline and lithium. In CSW volume 
and sodium substitution is necessary (hypertonic saline), [3, 7, 53]. There are further published 
studies using hydrocortisone [54, 55] and fludrocortisone [56]. 
Hyponatraemia in acute brain diseases is usually associated with CSW or SIADH. 
However, there are more types of hyponatraemia that can be also found in neurointensive care 
(table 5), [57], the most common being hyponatraemia caused by incorrect therapy or inadequate 
fluid replacement. 
Hyponatraemia is not always necessarily combined with a drop in serum osmolality. In 
some situations, there can be serum normoosmolality or even hyperosmolality, for example in 
hyperglycaemia, during mannitol osmotherapy or high serum levels of urea. 
Clinical signs are given by neurological symptoms from brain oedema, which is 
dangerous because the brain is located in a closed cranium. If brain volume by oedema increases, 
compensatory mechanisms in cranial space can be exhaustěd, leading to a rise in intracranial 
pressure (ICP), so-called intracranial hypertension, [39]. According to the level of TCP, 
neurological symptoms are changed, beginning with headaches, nausea, vomitting, 
desorientation, agitation, apathy, and going as far as seizures, deep unconsciousness and brain 
death. Clinical symptoms depend on the speed of development of hyponatraemia and 
compensatory mechanisms in cranial space and in brain cells. The aim of adaptive changes in 
brain cells is to lower intracellular osmolality. This leads to a drop in potassium and sodium 
(early changes - up to 24 hours) as well as the contents of organic compounds (later - up to 48 
hours). According to these adaptations hyponatraemia is divided into acute (up to 48 hours) and 
chronic (over 48 hours) stages. Neurological symptoms are often in acute hyponatraemia and 
steeper falls S_Na+. The border of acute hyponatraemia is below 130 inmol/1 and for chronic is 
120 mmol/1. 
Hyponatraemia tlicrapy is determined by the mechanism of its origin. The correction of 
sodium levels depends on the speed of the inception of hyponatraemia and the presence of 
neurological symptoms. 
Symptomatic hyponatraemia: 
Acute (up to 48 hours): quick corrections 1-2 mmol/l/hour 
Chronic (over 48 hours): slow corrections 0,5-0,6 mmol/l/hour 
Asymptomatic hyponatraemia: 0,5 mmol/l/hour. 
The basic aim in all extreme hyponatraemia is to achieve an increase in serum sodium of 
over 120 mmol/1 and the disappearance of neurological symptoms. Correction should be about 
12 mmol a day (from 10 to 15 minol/l/day), [14]. 
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During quick correction of hyponatremia there is a risk of neurological symptoms from 
myelin damage (demyelinisation syndrom). There are pontine and cxtrapontine myelinolysis 
[58-63]. CMP was first described by Adams in 1949 in alcoholic patients. He named it according 
to the localisation of lesion and damage to myelin. Malnutrition and alcoholism are among the 
risk factors of this syndrome. 
Hypernatremia in acute brain diseases 
Hypernatraemia is less frequent in acute brain disease than hyponatremia, but it is 
prognostically more serious [1, 64, 65]. Levels above 160 mmol/l are one of the independent 
markers of rising mortality [6], 
A typical, well-known syndrome associated with acute brain disease is central diabetes 
insipidus [66]. In the neurosurgical intensive care unit, however, it is not one of the more 
common types of hypernatraemia, making up a mere 3,7 % of all hypernatraemias, although it 
does have high mortality (72,4 %), [67]. It is most frequently found in SAH and TBT. In cDI 
hypernatraemia arises from water diuresis due to ADH insufficiency. There are three phases in 
its classic course. The initial diuretic period starts in 12 to 24 hours and lasts for 4 to 8 days. In 
the following antidiuretic phase, synthesised ADT-T from degenerating hypoiysis is released. 
Finally, in the third stage, there is again polyuria, which depends on the extent of brain damage 
and may be temporary or permanent. During polyuria, there can be more than 20 litres of 
diuresis a day [8]. Diagnosis is carricd out by observing hourly diuresis, urine osmolality, 
specific gravity of urine and renal function parametrcs (increased EWC), [19]. 
Central diabetes insipidus exists in two forms. Complete cDI occurs less frequently than 
partially incomplete cDI, in which water reabsorbtion is partially maintained in the case of large 
osmotic or hemodynamic stimuli. Diagnosis of the incomplete form of cDI can be earned out 
with the aid of responses to osmotic stimuli. Therapy for cDT is casual, and consists of the 
synthetic analogue desmopressin. In neurointensive care, parenteral treatment is preferred to 
nasal. Literature describes further medicine influencing ADH. Carbamazepine and 
chlorpropamide increase the ADH effect, clofibrate raises ADH secretion and thiazides are 
effective in the absence of ADH. Fluids are supplemented by using a different type of infusion 
according to serum sodium level, the speed of the decrease varies according to the 
recommendation for hypernatraemia. 
Besides central diabetes insipidus, nephrogenic diabetes insipidus [68, 69] is also 
known, and arises due to the inability of the kidney to respond normally to ADH. It can be 
caused by acutcly or chronically diseased kidneys, ion dysbalance and other factors. 
In neurointensive care there are usually multifactorial causes of hypernatraemia, most 
frequently to be found in connection with osmotherapy by mannitol. Another cause is renal 
failure [6]. 
Clinical symptoms are neurological and connected to dehydration of the brain. During 
hypernatraemia, a compensatory mechanism takes effect in the brain cells, which is in contrast to 
hyponatraemia. Effective osmolality of cells increase through retention of intracellular effective 
solutes. In the next few days, up to one week, synthesis of organic osmotic of active compounds 
rises. Neurological symptoms during hypernatraemia develop from restlessness, confusion and 
apathy to seizures and unconsciousness. Symptoms depend on the degree of hypernatraemia and 
speed of its inception. Acute hypernatraemia has clinical symptoms during serum levels of above 
150 mmol/l and chronic has sodium levels above 160 mmol/l. 
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Therapy of hypernatraemia is determined by the mechanism of these dysbalances. 
Correction of serum levels depends on the speed of hypernatraemia's inception. 
Acutc (up to 48 hours): quick corrections 1-2 mmol/l/hour 
Chronic (over 48 hours): slow corrections 0,5-0,7 mmol/lhour 
The decrease must not be more than 10-15 mmol/l/day. When there is no casual therapy we use 
hypotonic infusions and thiazides to correct sodium levels. 
Table 5. Hyponatraemia and hypernalraemia. 
' H y p o n a t r e m i a • ' ; - Hypernatnicmia 
Serum sodium < 1 3 5 mmol/l > 145 mmol/l 
Mechanism 
decrease the amount of sodium in 
ECT with regards to water 
increase the amount of sodium in 
ECT with regards to water. 
1) Sodium Sodium loss Sodium retention 
Gastrointestinal tract vomiting, diarrhoea, drainage use of salt 
Kidney 
hy poaldos teron i sm > 
hypocorticalism, uatriuresis in 
CSW, thiazides, nephropathia 
Skin 
sweating (inadequate fluid 
replacement), bums 
Others infusion NaCI and NaHCOj 
2) Water Water retention Water loss 
Gastrointestinal tract polydypsia diarrhoea 
Kidney STADH, renal failure 
central and nephrogenic diabetes 
insipidus, osmotic diuresis 
(glycosuria, urea, mannitol), 
Skin oedema 
sweating (inadequate fluid 
replacement), burns 
Others lungs, ICT / shift from ECT to cells 
Clinical signs 
neurological symptoms from brain 
oedema 
neurological symptoms from brain 
dehydration 
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The aims of tlic study 
1. Establishing calculated renal function parameters as pail of standard protocol when 
diagnosing and subsequently treating hyponatraemia and hypernatraemia in acute brain 
diseases. 
2. Making a prospective diagnostic protocol on the basis of retrospective data processing. 
3. Verification and evaluation of prospective standard protocol in diagnosing and 
monitoring therapy for hyponatraemia and hypernatraemia with the aim of assessing the 
clinical significance of established calculated renal function parameters. 
4. Determining the significance of NT-proBNP in differential diagnostics of hyponatraemia. 
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Methods 
Collection of patients 
The study was carried out in an eight-bed neurological-neurosurgical intensive care unit 
(NNICU) ill the Neuroceutre of Regional Hospital Liberec. Here patients with various acute 
brain and spinal diseases, both neurological and neurosurgical, are admitted. The most frequent 
diseases include acute strokes and brain tumours, trauma brain injuries (TBI) are less common. 
The NN1CU seizes for adult patients, children from the age of 7 are admitted exceptionally. 
Since 2001 theNNICU has hada systematic computer database of patients. 
Collections of patients and laboratory data were made from the database of Laboratory 
Information System Stapro (LTSSTA) Pardubice in the department of clinical biochemistry in 
Regional Hospital Liberec with the aid of the programme LisBed. The retrospective study was 
worked out from this database alone. The prospective study was additionally compared with the 
NNICU database. The criteria for patients' inclusion in the study was acute brain disease and 
serum sodium below 135 mmol/1 (hyponatraemia) and above 150 mmol/l (hypernatraemia). The 
basic characteristics of the patients can be seen in table 6 for the retrospective study and table 7 
for the prospective study. 
Table 6. Characteristics of the patients in the retrospective study. 
Parameter 
Hypo- Hyper- ^ 
p*value Dysaatraeniia nntiiiemin : natroemia 
Number of patients 326 (100,0%) 251 (100,0%) 75 (100,0%) 
1996 58(17,8%) 52 (20,7%) 6 (8,0%) 0,007 
1997 68 (20,9%) 59 (23,5%) 9(12,%) 0,024 
1998 62 (19,0%) 44(17,5%) 18(24,0%) 0,220 
1999 67 (20,6%) 45 (17,9%) 22 (29,3%) 0,037 
2000 71 (21,8%) 51 (20,4%) 20 (26,7%) 0,250 
Male 201 (61,7%) 160 (63,7%) 41 (54,7%) 0,159 
Age 54,6 years 53,9 years 56,8 years 0,268 
Stay in NNICU 11,7 days 11,8 days 11,6 days 0,221 
Focal brain lesion 203 (62,3%) 159(63,3%) 44 (58,7%) 0,465 
Diffuse brain lesion 123 (37,7%) 92 (36,7%) 31 (41,3%) 0,465 
Diagnosis 
Stroke 144 (44,2%) 101 (40,2%) 43 (57,3%) 0,009 
Tumour 100(30,7%) 80 (3!,9%) 20 (26,7%) 0,387 
Trauma 40(12,3%) 33 (13,1%) 7 (9,3%) 0,364 
Epilepsy 13 (4,0%) 12(4,8%) I (1,3%) 0,011 
Infection 13(4,0%) 13(5,2%) 0 (0,0%) 0,008 
Hydrocephalus 11 (3,4%) 7 (2,8%) 4 (5,3%) 0,309 
Other 5 (1,5%) 5 (2,0%) 0(0%) 0,104 
Operation 250 (76,7%) 188 (74,9%) 62 (82,7%) 0,153 
p-value — statistical significance between hypoiiatraemia and hypernatraemia, mean — in 
age and stay in NNICU. 
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Table 7. Characteristics of patients in the prospective study. 
Hypo- ' Hyper-
nntraemix p-vaiue 
"Parameter Dysnntrnemtn natraemia 
Number of patients 378 (100%) 245 (100%) 133 (100%) 0,009 
2001 42(11.1%) 27(11,0%) 15(11,3%) 1,000 
2002 39(10.3%) 17(6,9%) 22 (16,5%) 0,005 
2003 74(19.6%) 42 (17,1%) 32 (24,1%) 0,135 
2004 101 (26.7%) 72 (29,5%) 29 (21,8%) 0,116 
2005 122 (32.3%) 87 (35,5%) 35 (26,3%) 0,084 
Male 204 (54,0%) 132(53,9%) 72 (54,1%) 1,000 
Age (years) 58,4 ±14 ,2 57,2 ± 14,1 60,6 ± 14,1 0,022 
Weight (kg) 76,3 ± 15,0 76,0 it 14,8 76,9 ±15,3 0,561 
Stay ill NNICU (days) 11,1 ± 10,1 10,3 ± 9,8 12,6 ±10,6 0,035 
NYHA 1,4 ± 0 , 7 1,3 ± 0 , 6 1,5 ±0 ,7 0,008 
Focal brain lesion 202 (53,4%) 138(56,3%) 64(48,1%) 0,132 
Diffuse brain lesion 176 (46,6%) 107(43,7%) 69(51,9%) 0,132 
Diagnosis 
Stroke 198(52,4%) 110(44,9%) 88 (66,2%) <0,001 
Tumour 78 (20,6%) 59(24,1%) 19(14,3%) 0,024 
Trauma 57(15,1%) 38(15,5%) 19(14,3%) 0,880 
Epilepsy 15(4,0%) 14(5,7%) 1 (0,8%) 0,024 
Infection 14(3,7%) 10(4,1%) 4(3,0%) 0,778 
Hydrocephalus 10(2,6%) 9 (3,7%) 1 (0,8%) 0,175 
Other 6(1,6%) 5 (2,0%) 1 (0,8%) 0,670 
Operation 272 (72,0%) 161 (65,7%) 111 (83,5%) <0,001 
Type of operation 
Trepanation 33 (12,1%) 17(10,6%) 16(14,4%) 0,572 
Craniectomy 45 (16,5%) 21 (13,0%) 24(21,6%) 0,135 
Craniotomy 150(55,1%) 95 (59,0%) 55 (49,5%) 0,030 
Mean ± standard deviation, p-value - statistical significance between hyponatraemia and 
hypernatraemia. 
Observed clinical parameters 
The parameters nnder observation in the retrospective and prospective parts of the study 
differed slightly. The prospective study was extended on the basis of processed data from the 
retrospective part. In both studies we observed the indicators related to: 
the patient's prognosis: Glasgow Outcome Scale upon discharge from NNICU, 
mortality in NNICU, incidence of cerebral focal (haemorrhage, perifocal oedema) and 
diffuse complications (vasospasm, oedema, hydrocephalus), pulmonary oedema, 
onset of dysnatraemia: brain diagnosis, time from brain damage, focal or diffuse brain 
damage, Glasgow Coma Scale (GCS), operation (type and time since operation), relation 
to hospitalisation, therapy (diuretics and antidiuretics, antioedematic theraphy with 
mannitol or hypertonic saline) and type of infusions, 
length of dysnatraemia: time until normonatraemia, changes in natraemia in 24 hours 
and therapy of dysnatraemia, 
fluid balance: fluid intake (ml/day), fluid output (ml/day), fluid balance (ml/day). We 
calculated all fluids given by mouth, tube and parentally into fluid intake. Fluid output in 
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the retrospective study was only from diuresis and drainage due to inaccurate 
documentation. In the prospective study we calculated the overall fluid output including 
loss caused by fewer (200 ml per 1°C above 37°C) and skin loss (sweat). In neither study 
did we include metabolic water in fluid intake or immeasurable losses in fluid output. 
The prospective study was extended to include New York Heart Association 
classification, central venous pressure measurements and sodium intake. The overall sodium 
intake was calculated from parenteral and enteral nutrition. We did not include sodium in food. 
We also followed changes in consciousness during the onset of this dysnatraemia, and when the 
patients had computed tomography (CT) of the brain, we compared these findings with the 
previous ones. 
Observed biochemical parameters 
1. Measured parameters 
serum: sodium (S_Nai), potassium (S K4), calcium (S_Ca2+), magnesium (S_Mg24), chloride 
(S CI"), phosphorus (S_P), osmolality (S_Osm), proteins (SPrat), albumin (S_Alb), glucose 
(S GIu), urea (SUrea), creatinine (S_Cr), pH (B_pII). 
urine: osmolality (U_Osm), daily output of sodium (dUNa4), potassium (dLMC*), creatinine 
(dUCr), pH (U_pH), specific gravity of urine (Sp gr, the lowest and highest levels in 24 hours). 
Sodium, potassium and chloride measurements in seruin and urine were carried out on 
the COBAS Integra 800 (Roche, Diagnostics, Switzerland) machine by selective ion electrodes. 
Creatinine in serum and urine, magnesium, phoiphorus, calcium, proteins and albumin in serum 
were also measured on this equipment, but by photometric method. Osmolality was gauged on 
the cryoscopic osmometrc Fiske 210 (Advanced Instruments, Inc, Norwood, Massachusetts). 
B_pH was measured on the blood gas analyzer ABL 625 (Radiometer, Denmark). Assessment of 
urine pH (U_pH) was made on Urisys 2400 equipment (Roche Diagnostics, Switzerland). 
Specific gravity of urine was measured on the urometer in the NNICU. 
2. Calculated parameters 
Calculated osmolality (S OsmC), calculated effective osmolality (SOsmE), ratio urine and 
serum osmolality (U_Osm / S_Osm), ratio daily urine output of sodium and potassium (dU_Na+ 
/ dU_K+), creatinine clearance (C_Cr), osmotically active substances clearance (C Osm), 
electrolyte clearance (C_E1), sodium clearance (C_Na+), potassium clearance (C K4], solute free 
water clearance (C H2O), eletrolyte free water clearance (EWC), excretion fraction of 
osmotically active substances (FEOsm), excrction fraction of sodium (FE_Na+), excretion 
fraction of potassium (FE K4), excretion fraction of free water (FE H2O). 
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Formulae for calculated osmolality (S osmC) aod effective calculated osmolality 
(SosmE): 
SOsmC = 2 x Na+ + glucose + urea; 
SOsmE = 2 x Na+ + glucose. 
Formulae of renal function parameters: 
1) C_Cr = (UCr x V) / (Time x S Cr x Surface) 
2) C_Osm = (U_Osm x V) / (Time x SOsrn) 
3) C_E1 = V x [(U_Na+ + U_K+) + U_GIu] / [(S_Na+ + S_K+) + S_Glu] x Time 
4) C_Na+ = (U_Na+ x V) / (Time x S_Na*) 
5) C K4 = (U_K+ x V) / (Time x S_K+) 
6) C H20 = (V / Time ) - C_Osni 
7) EWC = (C Osm + C_H20) x (1 - (U_Na* + UK*)) I (S_Na+ + S_K+) 
8) FE Osm = (U_Osm x S_Cr) / (S_Osm x U C r x 1000) 
9) FE_Na+ = (U_Na+ x S_Cr) / (S_Na+ x U Cr x 1000) 
10) FE_K+ = (UK + x SCr) / (S K+xU_Cr x 1000) 
11) FE_HzO = S Cr / (U Cr x 1000) 
Clearance of creatinine (formula 1) was calculated according to general formulae for 
clearance with corrcction for the body's surface. Units of measured parameters in formulae are 
seen in table 8. Values of urine volume (V) are in litres and time in seconds. Biochemical 
parameters from urine were processed only from urine collected within 24 hours and with C_Cr 
above 1,15 ml/s. These renal function parameters bccame a component of the biochemical 
overview from the department of clinical biochemistry (formulae according "Encyclopaedia 
Laboratory Mcdicine", Jabor A, Zámečník J, Palička V). 
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Table 8. Overview of biochemical parameters observed in the retrospective 
and prospective study. 
Parameter Reference range 
Retrospective 
study 
Prospective 
study 
S Na* niniol/i 1 3 5 - 1 4 6 + + 
S K+ mmol/I 3 , 8 - 5 , 5 + + 
S Ca2+ mmol/l 2 - 2 , 7 5 + + 
S M g * ramal/1 0,7— 1,1 + + 
s c r mmol/l 97 — 108 H- + 
S ? mmol/l 0 , 7 - i,5 + + 
S Osm mmol/kg 2 7 5 - 2 9 5 + + 
S OsmC mmol/kg 2 7 5 - 3 0 0 + + 
S OsmE mmol/kg 272 - 290 + + 
S Prot fifl 6 5 - 8 0 + + 
S Alb g/1 3 2 - 5 3 + + 
S Glu mmol/l 3 , 3 - 6 , 1 + + 
S Urea mmol/] 2 , 8 - 7 , 5 + + 
S Cr umo 1/1 3 5 - 1 1 5 + + 
B pH 7 ,36-7 ,44 + + 
i"' ^ 
U Osm mmol/kg 50 - 850 + + 
U O s m / S Osm - + 
dU Na+ mmol/day 1 0 0 - 2 6 0 + + 
dU inmol/day 4 0 - 9 0 4 + 
dU Nah / dU K+ 1 0 0 - 2 6 0 - + 
C Cr ml/s 1 , 1 5 - 2 •h + 
C Osm ml/s 0,03 - 0,05 + + 
C El ml/s 0 ,011-0,023 + + 
C Na+ ml/s 0 ,008-0,016 •I- + 
C K+ ml/s 0 ,083-0 ,250 - + 
C HjO ml/s -0,027 - -0,007 + + 
C EWC ml/s -0,000 i/- 0,006 + + 
FE Osni 0 ,01-0 ,035 + + 
FE Na+ 0,004-0 ,012 + + 
FE K+ 0,040 - 0,190 - + 
FE HjO 0,01 - 0 , 0 2 + + 
U pH 5 , 0 - 6 , 0 - + 
Sp gr kg/m3 1015-1025 - + 
Study protocol 
The study is composed of two parts. The first part consists of retrospective evaluation of 
data in the period from 1.1.1996 to 31.12.2000. In the second part there is data processed 
according to prospective protocol for diagnosis of hyponatremia and hypernatraemia in the 
NNICU from 1.1.2001 to 31.12.2005. Both retrospective and prospective parts had the same 
five-year observation period. The prospective part was carricd out at the same time as the 
NNTCU database. In this period, from 2001 to 2005, 1546 patients with brain disease were 
admitted to the NNICU. 
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Retrospective study 
The retrospective study was processed first, the hyponatraemia and hypernatraemia 
collections separately. 
Hyponatraemia 
In the first phase we divided them according to measured serum osmolality (normal 
values 275 - 295 mmol/kg) into three groups: 1) hyponatraemia with osmolality in the reference 
range, 2) hyponatraemia with hyperosmolality (Sosm > 295 rtunol/kg) and 3) hyponatraemia 
with hypoosmolality (S_osm < 275 mmol/kg. In the next phase differential diagnostics were 
carried out by using measuring and calculating renal function parameters. CSW was evaluated 
separately, as were serum sodium values below 130 mmol/I. 
Hypernatraemia 
Firstly we diagnosed cDl according to hourly diuresis, urine osmolality, specific gravity 
of urine, renal function parameters and response to desmopressin. The remaining 
hypernatraemias were categorised "non cDl". We excluded patients without measured serum 
osmolality. Groups with serum sodium above 156 mmol/1 a 160 mmoi/i were processed 
sepcrately. 
Prospective study 
The prospective study took place according to standard protocol for diagnosing 
hyponatraemia and hypernatraemia (table 9). 
Til this prospective protocol, fluid balance was observed precisely, and in more serious 
eases hourly diuresis and CVP were measured. In patients with acute brain disease, scrum 
sodium was measured daily. As soon as dysnatraemia occurred, monitoring and examination 
according to prospective protocol were immediately introduced. Target values for serum sodium 
after 24 hours were set according to recommendations for sodium correction to avoid pontine 
and extrapontine myclinolysis. When there was a larger sodium shift, sodium measurements 
were taken more frequently, for example at intervals of every one or three hours. Diagnosis of 
dysnatraemia was made using renal function parameters. 
Hyponatraemia therapy in CSW consisted of continual administration of hypertonic 
saline and physiological solution. In polyuria, fludrocortisone was given. In cDl desmopressin 
was administered, mostly in parenteral form - intravenous bolus with an initial dose of 1 ug. 
Further doses were given according to the amount of diuresis. Therapy for other types of 
hypernatraemia consisted of administering thiazides diuretics. In all hypernatraemias different 
hypotonic infusions were applied according to serum sodium and recommendation for 
correction. 
Data processing was carried out in accordance with the retrospective study. 
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Table 9. Standard protocol for diagnosis of hyponatraemia and hypernatraemia inNNICU. 
P R O T O C O L FOR SODIUM DYSBALANCES 
in hyponatraemia (<135ininol/l) or hypernatraemia (> 15Qmmol/l). 
Abbreviation: Na protocol 
Cheek test tubes!!! Do not mix them up!!! 
Cheek written slips before handing over to laboratory!!! 
Check ordained blood tests +written slips—night shift. 
All blood tests written into patient documentation. 
Main times ofblood tests: 6 : 0 0 - 12 :00- 18:00-24:00 hours 
SAMPLES MUST NOT BE TAKEN FROM EXTREMITIES WHERE THERE IS AN 
TNFUSTON!!! 
6:00 hours 
Biochemical tests from blood: glucose, Na, K, CI, Ca, Mg, P, urea, creatinine, proteins, 
albumin, osmolality, blood gas. 
Blood count. 
Biochemical test from urine: osmolality, daily output (minerals, creatinine, urea), 
urinary casts, calculated renal function parameters. 
12:00 hours 
Basic minerals - Na, K, CI. 
18:00 hours Basic minerals, serum and urine osmolality. 
24: DO hours 
Basic minerals. 
Asscsment of N-terminal pro-B-typc Natriuretic Peptide (NT-proBNP) 
In the prospective study measurement of N-terminal pro-B-type Natriuretic Peptide (NT-
proBNP) was assessed in 40 patients with hyponatraemia and normal renal parameters. The basic 
characteristics of the patients can be seen in table 10. Statistical comparison between 
hypoosmolal and normoosmolal hyponatraemia was only carried out on patients catcgorised as 
NYHA I., (table 11). Further seperately group were patients with CSW and NYHA I. The control 
group was made up of patients with acute brain diseases according to the following criteria: 1) 
NYHA I. and 2) normal renal parameters. They were evaluated to the same clinical and 
biochemical parameters as in the hyponatraemia study. 
NT-proBNP was assessed using the electrochemiluminscence immunoassay ECLIA on 
the Roche Elecsys 2010 and modular analytics El 70 immunoassay analyzers utilizing the two-
site sandwich principle. The cutoff of 125 pg/ml was taken from the manufacturer's package 
insert. 
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Table 10. Characteristics of patients with NT-proBNI*. 
I'tfranVeler i Hypoitsítracmiá : NVtiinoiiiitiiiťniiii 
Number of patients 40 20 
Male 21 (52,5%) 12 (60%) 
Age (years) 53,5 ± 14,4 51,7 ± 12,9 
Weight (kg) 79,4 ± 15,7 77,6 ± 12,1 
Stay in NNICU 18,0* 10,8 19,3 ± 13,4 
NYHA 1,1 ± 0 , 4 1,0 ± 0 , 0 
Operation 24 (60%) 16 (80%) 
Stroke 21 (52,5%) 12(60%) 
Tumour 9 (22,5%) 3(15%) 
Trauma 4(10%) I (5%) 
Infection 1 (2,5%) 0 (0%) 
Epilepsy 2(5%) 1 (5%) 
Hydrocephalus 3 (7,5%) 2(10%) 
Other 0 (0%) 1 (5%) 
Mean ± standard deviation. 
Table 11. Characteristics of patients with NT-proBNP in hypoosmolal and normoosmolal 
hyponatraemia. 
Parameter 
Ifyp'obsiiiotnl 
- hyponatraemia 
: : Norňíobsíndlai 
: hyponatraemia p-value ; 
Number of patients pts 13 25 
Age years 46,3 ± 16,2 54,9 ± 11,8 0,069 
Weight (kg) kg 70,8 ± 12,4 80,8 ± 14,2 0,038 
Stay in NNICU day 18,2 ± 13,0 20,7 ±10,8 0,534 
Operation pts 9 (69%) 16(64%) 
Time since operation day 9,9 ± 11,5 10,6 ± 9 , 6 0,878 
Stroke pts 4 (31%) 14(56%) 
Tumour pts 4 (31%) 4 (16%) 
Trauma pts 3 (23%) 3 (12%) 
Infection pts 0 (0%) 1 (4%) 
Epilepsy pts 1 (8%) 1 (4%) 
Hydrocephalus pts 1 (8%) 2 (8%) 
Mean ± standard deviation, p-value - statistical significance between these groups. 
The prospective study was carried out with the approval of the hospital ethical 
committee. 
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Statistical processing 
The results were processed using the programme Statistica 7.0, StatSoft, Tnc. (2004) 
STATISTICA (data analysis software system, version 7, USA). The paramctric t-tcsl (normality 
of data) or non-paramctric M-W U test were used for differentiating connected variables. The 
ANOVA (normality of data) or non-parametric Kruskal-Wallis ANOVA test was used for 
differentiating between parameters in the three groups of patients. Comparison of categorical 
parameters was carried out with Fisher and M-L Chi-square tests. Correlation NT-proBNP with 
measured parameters was performed using Pearson (normality of data) or Spearman rank 
correlation. 
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Results 
Retrospective study 
In the five-year observation period there were 326 (100 %) patients (pts) with serum 
sodium dysbalances. The majority had hyponatremia (251 pts, 77 %). Hypernatracmia was less 
frequent, in 75 (23 %) pts (table 12). Overall there were 928 (100 %) days of dysnatraemia, 
usually hyponatremia (736 days, 79 %), less often hypcrnatraemia (192 days, 21 %), (table 12). 
Table 12. Characteristics of the retrospective study. 
\ . P a r a m e t e r : Dysnatracmiii 
. Hypo-
natraemia 
Hyper-
hatraemia p-value 
Number of patients pts 326 (100,0%) 251 (100,0%) 75 (100,0%) 
Operation pts 218(66,9%) 161 (64,1%) 57 (76,0%) 0,056 
After operation pts 107 (32,8%) 89 (35,5%) 18(24,0%) 0,056 
Time siuce operation day 5,5 ±6 ,5 6,2 ±6 ,5 3,7 ±5 ,0 0,002 
Cerebral complications pts 166 (50,9%) 115(25,8%) 51 (68,0%) 0,001 
Focal pts 103 (62,0%) 69 (60,0%) 34 (66,7%) 0,344 
Diffuse pts 98 (59,0%) 68 (59,1%) 30 (58,8%) 0,970 
No pulmonary oedema pts 317(97,3%) 247 (98,4%) 70 (93,3%) 0,480 
GOS 3,7 ± 1,2 3,9 ±1,1 3,3 ± 1 , 4 0,002 
Mortality in NNICU pts 20 (6,1%) 6 (2,4%) 14(18,4%) 0;001 
Days of dysnatraemia day 928(100,0%) 736(100,0%) 192 (100,0%) 
Lenght of dysnatraemia day 2,8 ±3 ,6 2,9 ± 3 , 8 2,6 ±2 ,8 0,713 
GCS 13,2 ±2 ,6 13,6 ± 2 , 2 12,0 ± 3 , 4 0,001 
Time siuce brain damage day 14,4 ± 18,8 14,4 ±17 ,7 14,2 ±22,1 0,359 
At admisson in NNICU pts 87 (26,7%) 74 (29,5%) 13(17,3%) 0,030 
Osmotherapy pts 156(47,9%) 101 (40,2%) 55 (72,4%) 0,001 
Mannitol pts 152(97,4%) 99 (98,0%) 53 (96,4%) 0,541 
Diuretics pts 31 (9,5%) 20 (8,0%) 11 (14,5%) 0,099 
Furosejuid pts 27 (87,1%) 16(80,0%) 11 (100,0%) 0,050 
Fluid intake ml/day 4000,9 ± 1504,0 3836,3 ±980,9 0,240 
Infusion ml/day 2020,3 ± 1334,1 2229,9 ±984,8 0,097 
Fluid output ml/day 3693,2±1856,3 3210,6±1199,8 0,018 
Diuresis ml/day 3550,9 ± 1849,3 3082,9 ± 1262,2 0,016 
Mean ± standard deviation, p-value - statistical significance between hyponatremia and hypematraemia, GCS -
on onset of dysnatraemia, GOS - Glasgow Outcome Scale upon discharge from NNICU. 
Hyponatremia 
Hyponatremia was most often Jinked with serum normooosmolatity (154 pts, 297 days) 
and sometimes with hyperosmolality (38 pts, 41 days), while a mere 50 patients (169 days) had 
hypoosmolalily (figure 1, table 13). The others were without measured serum osmolality. 
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Figure 1. Numbers of patients with hyponatraemi a in relation to measured serum osmolality. 
Normo osmolality -Hypo osmolality SHyperosmalality 
Hypoosmolal hyponatremia 
Over a five-year period hypoosmolal hyponatraemia was found in 50 pts. Renal function 
parameters were examined in 29 pts (58%), of whom 25 pts had CSW (table 14), the remaining 4 
pts suffered from hyponatraemia as a result of incorrectly prescribed desmopressin and nobody 
had SIADH.No patients had central pontine myelinolysis. 
Cerebral Salt Wasting 
CSW was found in 25 patients, 19 men and 6 women with the mean age 48,6 ± 17,9 
years. The mean stay in the NNICU lasted 20,4 ± 14,5 days. There were altogether 75 days of 
hyponatraemia, with an average duration of 4,9 ± 5,1 days. Mean GCS upon onset of 
hyponatraemia was 13,0 ± 2,5. The most frequent diagnosis in these patients was stroke (9 pts), 
second was TBI (8 pts). Cerebral complications appeared in 19 patients (76 %), two of whom 
died in the NNŤCU. The mean GOS was 3,8 ± 1,2. No patient had a pulmonary oedema. 22 
patients were treated with hypertonic saline, 7 of whom also received fludrocortisone. 
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Table 13. Characteristics of hyponatraemia in the retrospective study. 
J' • Parameter : •:.••"' : Hyppbsmolais y: Hyperósniúlal š aNoraíoósíťiolal p-value 
Number of patients pts 50(100,0%) 38(100,0%) 154 (100,0%) 
1996 pts 10(20,0%) 6(15,8%) 24 (15,6%) 0,767 
1997 pts 10(20,0%) 10 (26,3%) 40 (26,0%) 0,668 
1998 pts 8 (16,0%) 7(18,4%) 35 (22,7%) 0,544 
1999 pts 11 (22,0%) 6(15,8%) 30(19,5%) 0,762 
2000 pis 11 (22,0%) 9 (23,7%) 25(16,2%) 0,458 
Male pts 37 (74,0%) 22 (57,9%) 105 (68,2%) 0,278 
Age years 48,5 ± 18,9 53,9 ± 14,4 55,2 ± 15,2 0,089 
Stay in NNICU day 18,7 ± 12,7 9,8 ±10,4 13,7 ± 11,2 0,001 
Focal brain damage pis 28 (56,0%) 28 (73,7%) 98 (63,6%) 0,226 
Diffuse brain damage pts 22 (44,0%) 10 (26,3%) 56 (36,4%) 0,226 
Stroke pts 17(34,0%) 13 (34,2%) 65 (42,2%) 0,458 
Trauma pts 13 (26,0%) 4(10,5%) 19(12,3%) 0,061 
Tumour pts 9(18,0%) 18(47,4%) 52 (33,8%) 0,010 
Epilepsy pts 1 (2,0%) 1 (2,6%) 4 (2,6%) 0,969 
Infection pts 4 (8,0%) 2 (5,3%) 6 (3,9%) 0,538 
Hydrocephalus pts 5(10,0%) 0 (0,0%) 5 (3,2%) 0,035 
Others pts 1 (2,0%) 0 (0,0%) 3 (1,9%) 0,502 
Operation pts 43 (86,0%) 30 (78,9%) 127(82,5%) 0,683 
Days after operation day 11,4 ±9,0 4,2 ±3 ,7 7,5 ± 7,8 0,002 
Cerebral complications pts 35 (70,0%) 16(42,1%) 79(51,3%) 0,019 
Focal pts 22 (62,9%) 9 (56,3%) 45 (57,0%) 0,824 
Diffuse pts 22 (62,9%) 13(81,3%) 51 (64,6%) 0,358 
No pulmonary oedema pts 49 (98,0%) 37 (97,4%) 150 (97,4%) 0,969 
C.OS 3,8 ±1,2 3,8 ± 1,2 3,8 ± 1,1 0,956 
Mortality in NNICU pis 3 (6,0%) 2 (5,3%) 5 (3,2%) 0,660 
S Na+ mmol/1 129,6 ±4,0 132,3 ±2,6 132,5 ±1 ,7 0,001 
S Na+ 130-134 day 104 (61,5%) 36 (87,8%) 278 (93,6%) 
S Na+ <130 day 65 (38,5%) 5 (12,2%) 19(0,3%) 
Shift (+) S_Naf in 24 h mmol/1 4,9 ±'3,8 4,2 ±3 ,8 4,0 ± 3,1 0,173 
Days of dysnatraemia day 169(33%) 41 (8%) 297 (59%) 
Length of dysnatraemia day 3,4 ±4 ,0 1,1 ±0,2 1,9± 1,7 0,001 
CCS day 13,1± 2,3 13,5 ±2,5 13,5 ±2 ,3 0,001 
Since brain damage day 18,0 ± 18,6 10,5 ± 2 2 18,7 ± 2 0 0,001 
Admission in NNICU pts 11 (22,0%) 15(39,5%) 30(19,4%) 0,043 
Antioedematic therapy pts 11 (22,0%) 22 (57,9%) 60 (38,7%) 0,002 
Mannitol pts 11 (100,0%) 22(100,0%) 58 (96,7%) 0,406 
Fluid intake ml/day 4153,9 ± 1221,9 3339,2 ± 856,5 3957,5 ± 1695,2 0,005 
Infusion ml/day 2038,5 ±1108,2 1983,2 ± 772,7 2007,6 ± 1506,0 0,994 
Fluid output ml/day 3930,4 ± 1675,9 2600,0± 1012,6 3619,5 i l 997,1 0,001 
Diuresis nil/day 3799,5 ± 1670,3 2418,8 ± 1018,4 3+79,7± 1983,8 0,001 
Fluid balance - negative day 50 (29,6%) 1 (2,4%) 65 (21,9%) 0,001 
S Osm mmol/kg 267,3 ± 6,4 303,9 ±7 ,9 283,0 ± 5,4 0,001 
S OsmC mmol/kg 269,2 ± 8,6 284,4 ±9,0 277,8 ± 4,9 0,001 
S OsmC mmol/kg 265,4 ±8,0 274,2 ±5 ,5 272,0 ±4,1 0,001 
U Osm mmol/kg 509,5 ±178,9 571,1 ±205,5 575,8 ±190,7 0,003 
S KT mmol/1 4,1 ±0,5 4,5 ± 0,7 4,2 ± 0,6 0,006 
S Alb g/1 36,7 ± 4,8 37,4 ±6,0 37,4 ±4,7 0,733 
S_Glu mmol/1 6,1 ± 1,3 9,8 ±5,2 7,0 ±2 ,4 0,001 
S Urea mmol/1 3,9 ±1 ,6 9,9 ±6 ,9 5,8 ±2,7 0,001 
S Cr umol/1 67,8 ±15,0 118,9 ± 129,8 78,0 ±53,1 0,001 
B PH 7,438 ± 0,045 7,421 ± 0,057 7,436 ± 0,042 0,237 
Mean ± standard deviation, p-value -statistical significance between these groups, GCS - on onset of dysnatraemia, 
admission to NNICU - dysnatraemia present on admission. 
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Tabic 14. Characteristics of patients with CSW. 
. . . . . . . -IgsPaMmQéf-ša- - - " v':!Viean : S P Median "přyatue • 
S_Na~ mmol/1 129,5 3,4 130,0 <0,001 
S_Na+ 130-134 mmol/1 131,9 (N42) 1,5 132,0 <0,001 
S_Na+ <130 mmol/1 126,5 (N33) 2,6 127,0 <0,001 
Shift (+) S_Na+ in 24 h mmol/i 5,5 3,7 5,0 <0,00! 
S O s m juinol/kg 267,5 5,8 269,0 <0,001 
S O s m C mmo1/kg 268,8 7,5 269,0 <0,001 
S O s m E mm of/kg 265,3 7,0 265,0 <0,001 
U O s m mmol/kg 537,6 171,3 528,5 <0,001 
S_K* mmol/l 4,1 0,5 4,1 
S_A1b g/l 37,4 4,8 37,7 
S G l u mmol/1 5,9 u 5,7 
S U r e a mmol/1 3,6 1,6 3,4 
S_Cr umol/1 66,4 13,9 65,0 
B_PH 7,429 0,041 7,429 
dU_Na+ ml/day 546,6 383,7 507,0 <0,001 
d U K * ml/day 66,3 38,5 60,1 <0,001 
C_Cr ml/s 2,2 0,6 2,1 0,053 
C O s m ml/s 0,092 0,042 0,084 <0,001 
C_EI ml/s 0,065 0,036 0,057 <0,001 
C N a * ml/s 0,061 0,036 0,052 <0,001 
C H j O iuI/S -0,042 0,034 -0,044 <0,001 
EWC ml/s -0,015 0,032 -0,013 <0,001 
F E O s m 0,045 0,021 0,039 0,001 
F E N a " 0,029 0,016 0,025 <0,001 
Fluid intake ml/day 4464,1 1464,4 4200,0 
Tnfiision in l/day 2239,4 1229,3 1950,0 
Fluid output ml/day 4270,4 1856,1 3925,0 
Diuresis ml/day 4175,8 1869,6 3900,0 
Fluid balance - negative ml/day 890,7 (N=29) 661,1 800,0 
Fluid balance - positive ml/day 1113,4 1378,1 800,0 
SD — standard deviation, p-value - statistical significance with respect to the reference range, N - all 
days. 
Hyponatraemia with serum sodium below 130 mmol/1 
From 251 patients with hyponatraemia, only 51 (21 %) were recorded with serum sodium 
below 130 mmol/1. Altogether there were 106 days, the majority of which were with serum 
hypoosmolality (65 days), fewer with normoosmolality (19 days) and the fewest with 
hyperosmolality (5 days), (table 15). The remainder were without measured serum osmolality. 
11 
Table 15. Characteristics of hyponatraemia with serum sodium below 130 mmol/1. 
Parameter < 130 iuwOJ/1 
•: •' s Na+ : : : 
130--J34mol/l p-value 
Stay in NNICU day 16,7 ±12,8 10,5 ±9 ,5 <0,001 
Cerebral complications pts 37 (72,6%) 78 (39,4%) <0,001 
Focal pts 23 (62,2%) 46 (59,0%) 0744 
Diffuse pts 23 (62,2%) 45 (57,7%) 0,648 
GCS 13,0 ± 2 , 3 13,8 ±2,1 0,018 
GOS 3,7 ± 1,1 3,9 ± 1,1 0,152 
Mortality in NNICU ' pts 3 (5,9%) 3(1,5%) 0,103 
Days of dysnatraemia day 6,3 ± 6,6 2,1 ±1,4 <0,001 
Length of dysnatraemia day 106(100,0%) 630 (100,0%) 
Antioedematic therapy pts 21 (41,2%) 80 (40,4%) 0,920 
Mannitol pts 21 (100,0%) 78 (97,5%) 0,332 
Fluid intake ml/day 4122,6± 1261,8 3975,2± 1550,9 0,457 
Infusion nil/day 1972,1 ±985,8 2030,5 ± 1397,5 0,740 
Fluid output rul/day 3887,8 ± 1574,9 3651,1 ± 1911,4 0,348 
Diuresis ml/day 3717,4± 1593,1 3514,8 ± 1900,6 0,413 
Mean ± standard deviation, p-value -statistical significance between these groups, GCS — an onset of 
dysnatraemia, GOS — Glasgow Outcome Scale in discharge of NNICU, admission to NNICU -
dysnatraemia present upon admission. 
Hypernatraemia 
Of the 75 patients with hypernatraemia, cDI was found in only 8 of them (15 days). We 
classified 59 patients as "non-cDl" (163 days), (table 16). The remaining patients were not 
evaluated because they had no serum osmolality measurements. 
Hypernatraemia with serum sodium above 156 mmol and 160 mmol 
From the 75 hypematraemic patients, 25 had (33 %) S_Na+ above 156 mmol/1 and 12 (16 
%) had S_Na+ above 160 mmol/1. in a comparison of both extreme groups with all 
hypernatraemias we found significantly longer durations of hypernatraemia (for both groups p < 
0,001) and higher mortality in the NNICU (S_Na+ above 156 mmol/1 p = 0,041, S_Na+ above 
160 mmol/1 p = 0,040). However, we did not found any significant changes between these 
extreme groups (table 17). 
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Table 16. Characteristics of hypcrnalraeroia in the retrospective study. 
Parameter . : CDI ;r )• -noh cDÍ • p-value 
Number of patients pts 8(100,0%) 59(100,0%) 
1996 pts 0 (0,0%) 2 (3,4%) 0,767 
1997 pts 2 (25,0%) 6(10,2%) 0,668 
1998 pts 3 (37,5%) 16(27,1%) 0,544 
1999 pts 2 (25,0%) 20 (33,9%) 0,762 
2000 pts 1 (12,5%) 15 (25,4%) 0,458 
Male pts 2 (25,0%) 30 (50,8%) 0,278 
Age years 46,4 ± 13,3 58,3 ± 15,3 0,089 
Stay in NNICU day 15,8 ±10,5 11,9 ± 10,3 0,001 
Focal brain lesion pts 4 (50,0%) 36(61,0%) 0,226 
Diffuse brain lesion pts 4 (50,0%) 23 (39,0%) 0,226 
Stroke pts 4 (50,0%) 30 (50,8%) 0,507 
Tumour pts 3 (37,5%) 17(28,8%) 0,789 
Trauma pts 0 (0,0%) 7(11,9%) 0,222 
Operation pts 7 52 0,767 
After operation pts 6 48 0,444 
Days after operation day 3 ,8± 5,1 3,0 ± 4,0 0,352 
Cerebral complications pts 5 (62,5%) 39 (66,1%) i.OOO 
Focal pts 2 (40,0%) 29 (74,4%) 0,283 
Diffuse pts 4 (80,0%) 21 (53,8%) 0,380 
No pulmonary oedema pts 8(100,0%) 54(91,5%) 0,307 
GOS 3,5 ± 1 , 7 3 ,4± i ,3 0,857 
Mortality iuNNICU pts 2 (25,0%) 7(11,9%) 0,210 
S NaŤ nunol/1 155,0 ± 5,5 (N=15) 154,5 ±3 ,7 (N=149) 0,736 
S Na+ 151 -155 mmol/1 152,4 ± 1,2 (N=I1) 152,6 ± 1,3 (N=I04) 0,638 
S Na+ 156-160 mmol/l 157,5 ± 0,7 (N=2) 157,4 ± 1,2 (N=32) 0,770 
S Na+ >160 mmol/1 167 ± 5,7 (N=2) 163,3 ± 3,2 (N=13) 0,234 
Shift (-) S_Na' in 24 li mmol/l 6,7 ±4 ,7 6,1 ±4,1 0,757 
Length of dysnatraEmia day 5,3 ± 7,3 2,8 ± 3,0 0,706 
GCS 11,0 ±5 ,3 12,6 ±2 ,6 0,631 
Since brain damage day 14,0 ± 15,0 14,4 ±24,3 0,370 
Admission to NNICU pts 3 (37,5%) 10(16,9%) 0,319 
Antioedematic therapy pts 3 (37,5%) 48 (81,4%) 0,013 
Mannitol pts 3(100,0%) 47(97,9%) 0,772 
Diuretics day 2(13,3%) 63 (42,3%) 0,019 
Furosemid day 0 (0,0%) 40 (63,5%) 0,048 
Fluid intake ml/day 4036,4 ±874,4 3803,0 ± 985,3 0,450 
Infusion ml/day 2368,2± 1511,7 2203,0 ± 944,0 0,281 
Fluid output ml/day 3876,7± 1815,8 3!39,2 ± 1115,8 0,074 
Diuresis ml/day 3771,1 ±1821,3 3008,7 ± 1188,9 0,079 
Fluid balance - negative day 2 (13,3%) 18(12,1%) 0,889 
S_Osm mmol/kg 323,3 ± 15,4 326,4 ± 16,0 0,476 
S O s m C mmol/kg 325,6± 13,4 326,1 ± 10,9 0,558 
S O s m E mmol/kg 318,3 ± 11,3 316,5 ±8,5 0,555 
U Osm mmol/kg 392,3 ±221,9 578,8 ±186,7 0,001 
S iC mmol/l 4,0 ± 0 , 4 3,9 ±0 ,5 0,656 
S G l u mmol/l 8,4 ± 2 , 0 7,4 ± 2 , 9 0,010 
S Urea mmol/l 7,0 ± 2 , 9 9,6 ± 5 , 3 0,075 
S Cr umol/l 96,3 ± 19,7 95,1 ±37 ,0 0,387 
B PH 7,422 ±0,033 7,429 ±0,051 0,679 
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Table 17. Comparison of hypematraemia with serum sodium above 156 mmol/1 and 160 mmol/1. 
. '•"."• Psiranieter •ÍÍ7.
 : - - U ' S J S H Í ? ; 
•* > 156 miiiDl/1 
L' § f"-r S .Na*v : 
; > 160 miw>(S"J; 
ííš-ýálUě 
Number of patients pts 25(100,0%) 12(100,0%) 
Stay in NNICU day 12,6 ±10,9 15,5 ± 13,6 0,490 
Length of dysnatraemia day 4,2 ±4 ,2 5,3 ± 5,7 0,721 
GCS 11,2 ±4 ,2 10,0 ± 4 , 6 0,355 
GOS 2,8 ± 1,6 2,5 ± 1 , 6 0,592 
Mortality in NNICU pis 8 (32,0%) 5 (41,7%) 0,567 
Mean ± standard deviation, p-yaliie - statistical significance between these groups. 
Prospective study 
In the five-year observation period, serum sodium dysbalances occurred in 24 % patients 
with acute brain diseases admitted to ourNNlCU. There were 378 (100 %) patients, the majority 
had hyponatremia (245 pts, 65 %). Hypematraemia was less frequent, in 133 (35 %) pts (table 
18). Overall there were 1089 (100 %) days of dysnatraemia, usually hyponatremia (661 days, 
61 %), less often hypematraemia (428 days, 39 %), (table 115). 
Hyponatremia 
Hyponatraemia occurred in 245 pis. Overall there were 661 days of dysnatraemia, which 
was most often linked with serum normooosmolality (429 days) and sometimes with 
hyperosmolality (52 days), while a mere 50 patients (105 days) had hypoosmolality (figure 2, 
table 19). The others were without measured serum osmolality. 
Figure 2. Days of hyponatraemia in relation to measured serum osmolality. 
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Table 18. Characteristics of the prospective study. 
, ; PBřflrnef^ DysiÍBfraexpiriliv 
" . - • H y p o - ' 
ínijtraemia 
:-_7'jITypVř- v 
iiiatrsiemia 
: p-value -
Number of patients pts 378(100%) 245(100%) 133(100%) 0,009 
Operation pts 272 (72,0%) 161 (65,7%) 111 (83,5%) <0,001 
After operation pts 222 (58,7%) 115(46,9%) 107 (80,5%) <0,001 
Time since operation day 6,1 ±8 ,6 7,4 ± 8 , 9 4,8 ±8 ,1 0,020 
Cerebral complications pts 210(55,6%) - 105 (42,9%) 105 (78,9%) <0,001 
Focal pts 146(69,5%) 72 (68,6%) 74 (70,5%) 0,881 
Diffuse pts 142(67,6%) 66 (62,9%) 76 (72,4%) 0,184 
Oedema pts 64(45,1%) 20 (30,3%) 44 (57,9%) 0,001 
Vasospasms pts 39 (27,5%) 20 (30,3%) 19 (25,0%) 0,572 
Hydrocephalus pts 32 (22,5%) 18 (27,3%) 14(18,4%) 0,232 
Pulmonary oedema pts 22 (5,8%) 9 (3,7%) 13(9,8%) 0,021 
GOS 3,3 ± 1,3 3 ,8± 1,1 2,4 ±1 ,2 <0,001 
Mortality in NNICU pts 58(15,3%} 15 (6,f%) 43 (32,3%) 0,003 
Days of dysnatraemia day 1089(100%) 661 (100%) 428(100%) 
Length of dysnatraemia day 2,9 ± 2 , 6 2,7 ±2 ,8 3,2 ±2 ,2 0,059 
On admisson to NNICU pts 143 (37,8%) 134 (54,7%) 9 (6,8%) <0,001 
GCS 11,7 ±4 ,1 13,3 ± 3 , 0 9,4 ± 4 , 3 <0,001 
Consciousness pts <0,001 
Regression pts 13 (3,4%) 6 (2,4%) 7 (5,3%) 0,235 
Without change pts 204 (54%) 156(63,7%) 48 (36,1%) <0,001 
Progression pts 97(25,7%) 20 (8,2%) 77 (57,9%) <0,001 
CT of bTain pts <0,001 
Regression pts 21 (5,6%) 9 (3,7%) 12(9,0%) 0,036 
Without change pts 15 (4,0%) 11 (4,5%) 1 (3,0%) 0,589 
Progression pts 56 (14,8%) 11 (4,5%) 45 (33,8%) <0,001 
Time from brain damage day 9,9 ±9 ,2 11,8 ± 9,1 7,6 ±8 ,7 <0,001 
Acute onset pts 285 (75,4%) 154 (62,9%) 131 (98,5%) <0,001 
impossible - admission pts 84 (22,2%) 83 (33,9%) 1 (0,8%) <0,001 
Osmotherapy pts 208 (55%) 95 (38,8%) 113(85,0%) <0,001 
Mannitol pts 94 (45,2%) 49 (51,6%) 45 (39,8%) 0,212 
NaCI 10% pts 164(78,8%) 63 (66,3%) 101 (89,4%) <0,001 
Diuretics pts 90 (23,8%) 32(13,1%) 58 (43,6%) <0,001 
Furoscmid pts 68 (75,6%) 13(40,6%) 55(94,8%) . <0,001 
CVP torr 5,5 ±3 ,8 5,8 ±3,1 5,5 ± 4,0 0,684 
Fluid intake ml/day 3613,2 ±748,9 3535,1 ±711,0 3710,6 ± 783,7 <0,001 
Sodium intake mmol/day 415,5 ± 187,6 408,9 ± 188,6 423,8 ± 186,3 0,262 
Fluid output ml/day 3169,5± 1135,8 3287,5 ± 1038,3 3022,3 ± 1232,5 0,001 
Diuresis ml/day 3030,3 ±1156,1 3213,7± 1037,7 2802,8 ± 1252,7 <0,001 
dU_Na+ inmol/day 558,8 ± 211,9 374,6 ± 185,3 <0,001 
dU_Na+/dU_K+ 7,9 ±4 ,8 3,7 ±2 ,3 <0,001 
C_Cr ml/s 1,8 ±0 ,5 1,7 ±0 ,4 0,011 
C O s m ml/s 0,074 ±0,022 0,060 ±0,018 <0,001 
C H I mf/s 0,054 ± 0,020 0,035 ±0,015 <0,001 
C_Na+ ml/s 0,049 ±0,019 0,028 ±0 ,014 <0,001 
C H , 0 inl/s -0,037 ±0,018 -0,027 ±0,013 <0,001 
EWC ml/s -0,017 ±0,016 -0,002 ±0 ,012 <0,001 
F E O s m 0 ,040±0,0 l2 0,035 ±0 ,009 <0,001 
FENa~ 0,026± 0(011 0,016±0,008 <0,001 
F E H j O 0,021 ±0,008 0,020 ±0,008 0,160 
Mean ± standard deviation, p-value - statistical significance between hyponatraemia and hypematraemia, GCS - on 
onset of dysnatraemia, GOS - Glasgow Outcome Scale upon discharge of NNICU, impossible - admission -
founded on admisson. 
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Tabic 19. Characteristics of hyponatraemia in the prospective study. 
Parameter" - Hypoosmolal Hyperosmolar : Normoosmolal" p -va lues 
Number of patients pts 55 (100,0%) 45 (100,0%) 184(100,0%) 
Male pts 28 (50,0%) 20 (40,0%) 84 (50,0%) 0,756 
Age years 73,5 ± 12,5 77,8 ± 17,1 57,1 ± 1 3 , 9 0,224 
Stay in NNICU day 14,5 ±11 ,1 8,0 ± 9,1 11,8± 10,4 0,001 
Stroke pts 27(49,1%) 15 (33,3%) 87 (47,3%) 0,194 
Trauma pts 10(18,2%) 6(13,3%) 27(14,7%) 0,769 
Tumour pts 9(16,4%) 20 (44,4%) 39(21,2%) 0,003 
Operation ptš 35 (63,6%) 32 (71,1%) 120 (65,2%) 0,697 
Days after operation day 13,9 ± 1 5 , 5 2,7 ± 3 , 7 8,5 ± 7,6 <0,001 
Cerebral complications pts 31 (56,4%) 13 (28,9%) 88 (47,8%) 0,017 
Pulmonaiy oedema pts 1 (1,8%) 4 (8,9%) 7 (3,8%) 0,231 
GOS 3,8 ± 1 , 2 3,8 ±1,0 3,7 ± 1,1 0,856 
S NÍH- mmol/i 129,2 ± 4 , 5 132,8 ± 2 , 1 132,8 ± 1,4 <0,001 
S Na" 130-134 day 60 (57,1%) 49 (94,2%) 415(96,7%) <0,001 
S Na ' <130 day 45 (42,9%) 3 (5,8%) 14(3,3%) <0,001 
Shift (±) S > ' a ' in 24 h mmol/l 5,5 ± 4,7 4,6 ± 2,8 3,5 ± 2 , 6 <0,001 
Days of dysnatraemia day 105 (100,0%) 52 (100,0%) 429(100,0%) 
Length of dysnatraemia day 1,9± 1,2 1,2 ± 0 , 5 2,3 ± 2,4 <0,001 
GCS 13,0 ± 3 , 3 13,1 ± 3 , 7 13,2 ±3 ,1 0,666 
Since brain damage day 15,5 ± 14,4 11,1 ±9 ,1 11,9 ± 9 , 5 0,406 
Acute onset pts 36 (65,5%) 26 (57,8%) 135 (73,4%) 0,105 
Impossible - admission pts 17(30,9%) 18(40%) 44(23,9%) 0,091 
Osmotherapy day 59 (56,2%) 45 (86,5%) 293 (68,3%) <0,001 
Manitol day 12(20,3%) 30 (66,7%) 64(21,8%) <0,001 
Diuretics day 11 (10,5%) 9(17,3%) 67(15,6%) 0,337 
Fluid intake ml/day 3855,6 ±867 ,8 3058,1 ± 394,6 3476,9 ±678,1 <0,001 
Infusion ml/day 2143,5 ±877 ,0 1601,9 ± 560,1 1952,1 ± 6 8 3 , 4 0,040 
Sodium intake mmol/day 462,8 ± 223,3 347,8 ± 109,3 410,1 ± 188,7 0,135 
Sodium intake mmol/kg/ day 6,5 ± 3,2 5,0 ± 1,6 5,5 ± 2 , 7 0,068 
Fluid output ml/day 3595,1±1152,2 2636,2 ± 606,4 3242,7 ± 998,5 0,003 
Diuresis ml/day 3502,4 ± 1135,9 2555 ±561 ,8 3174,9 ± 1007,9 0,003 
Fluid balance - negative day 25 (23,8%) 5 (9,6%) 114(26,6%) 0,979 
S Osm mmol/kg 267,4 ± 7,8 302,3 ± 6,0 283,6 ± 5,3 <0,001 
S O s m C mmol/kg 267,7 ± 9,0 283,3 ± 8,3 277,2 ± 4 , 0 <0,001 
U O s m mmol/kg 525,1 ± 177,5 644,5 ± 178,4 612,7 ± 168,8 <0,001 
U Osm/S Osm 2,0 ± 0 , 7 2,1 ± 0,6 2,2 ± 0,6 0,018 
S 1C mmol/l 4,0 ± 0 , 5 4,4 ± 0,5 4,1 ± 0 , 5 <0,001 
S G I u mmol/l 5,8 ± 1,4 9,0 ± 4 , 0 6,4 ± 1,8 <0,001 
S Urea mmol/l 3,9 ± 1,4 8,6 ± 5 , 2 5,2 ± 2,2 <0,001 
S Cr umol/l 69,2 ± 1 4 , 9 94,3 ± 47,9 71 ,2± 19,1 <0,001 
B PH 7,4 ± 0,D 10,1± 18,3 7,4 ± 0 , 0 <0,001 
dU Na" mmol/day 638,8 ± 232,2 510,1 ± 105,1 544,8 ± 209,9 0,040 
dU Na+ /dU K+ 8,2 ± 5 , 1 11,4 ± 2,8 7,6 ± 4 , 7 0,002 
C_Cr ml/s 2,1 ± 0 , 5 1,6 ± 0 , 5 1,8 ± 0 , 4 <0,001 
C Osm ml/s 0,083 ±0 ,025 0 ,064±0,010 0,073 ± 0,022 0,030 
C Ei IDI/S 0 ,062±0,021 0,045 ± 0,008 0,053 ± 0 , 0 1 9 0,016 
C Na ml/s 0,057 ±0,021 0,044 ± 0,009 0 ,047±0,018 0,017 
C HiO ml/s -0,042 ±0 ,020 -0,034 ± 0,008 -0,036 * 0 , 0 1 8 0,137 
EWC ml/s -0 ,022±0,018 -0,015 ± 0,006 -0 ,016± 0,015 0,100 
FE Osm 0,041 ±0 ,014 0,041 ±0 ,010 0,040 ±0 ,012 0,908 
FE Nif 0 ,028±0 ,012 0,028 ±0 ,009 0 ,026± 0,010 0,399 
FE H-,0 0,020 ±0 ,008 0 ,019±0,006 0,022 ±0 ,008 0,435 
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H y p o o s m o l a l h y p o n a t r e m i a 
Over a five-year period hypoosmolal hyponatraemia was found in 55 pts. CSW was 
diagnosed in 26 pts (table 20). In two cases the cause of hyponatraemia was incorrectly 
administered therapy, in one instance desmopressin and in the second an unsuitable dose of 
hypotonic solutions. No patient had SIADH. 
For the remaining patients (27), it was impossible to carry out differential diagnostics 
because the renal function parameters were missing. Eighteen of them had one-day hypoosmolal 
hyponatraemia, which was in 12 cases discovered upon admittance to the NNICU. A further 6 
patients had two-day hyponatraemia. Renal function parameters were not taken for the others, 
even though they had hyponatraemia for three or four days. 
43 patients were given NaCl (10 %) concentrated solution, while 22 patients received 
fludmcortizon. 
No patients had central pontine myelinolysis. 
Cerebral Salt Wasting 
CSW was found in 26 patients, 15 men and 11 women with the mean age 50,4 ± 15,3 
years. The mean stay in the NNICU lasted 18,2 ± 11,3 days. There were altogether 100 days of 
hyponatraemia. with an average duration of 6,5 ± 4,0 days. Mean GCS upon onset of 
hyponatraemia was 12,8 ± 3,3. The most frequent diagnosis in these patients was stroke (12 pts), 
then tumour (6 pts) and TBI (5 pts). Cerebral complications appeared in 17 patients (65,4 %), 
two of whom died in the NNTCU. The mean GCS was 3,8 ± 1,2. No patient had a pulmonary 
oedema, 22 patients were treated with hypertonic saline, 7 of whom also received 
fludrocortisone. Further parameters are shown in table 20. 
Hyponatraemia with serum sodium below 130 mmol/1 
From 245 patients with hyponatraemia, only 46 (19%) were recorded with serum sodium 
below 130 mmol/l. Altogether there were 66 days, the majority of which were with serum 
hypoosmolality (45 days), fewer with normoosmolality (14 days) and the fewest with 
hyperosmolality (4 days), (table 21). The remainder were without measured serum osmolality. 
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Table 20. Parameters in patiensts with CSW in the prospective study. 
'"•_•*. . Parameter *:1 . Mean fysb;- Median p-ýa.lue: 
S_Na+ mmol/I 130,9 3,8 133,0 <0,001 
S_Na+ 130 -134 mmol/I 132,8 (N=74) 1,2 133,0 <0,001 
S_Na+ <130 mmoJ/1 125,6 (N=26) 3,5 127,0 <0,001 
Shift (+) S_Na+ in 24 h mmol/i 3,9 3,3 3,0 <0,001 
S O s m mmol/kg 273,7 9,0 273,0 <0,001 
S O s m C mmol/kg 270,5 8,8 273,0 <0,001 
S O s m E mniol/kg 267,5 8,4 271,0 <0,001 
U O s m minol/kg 591,9 157,1 591,0 <0,001 
U_Osm/S_Osm 2,2 0,6 2,2 
S G I u mmol/1 6,2 2,5 5,3 
SUrea mmol/I 3,7 1,3 3,5 
S_Cr umo 1/1 64,8 12,9 64,0 
B_PII 7,4 0,0 7,4 
dU_Na+ mmol/day 654,2 212,9 619,5 <0,001 
d U J C mmol/day 90,4 34,1 85,3 0,936 
dU_Na7dU_K+ 8,2 4,4 7,6 
C_Cr ml/s 2,0 0,5 2,0 
C O s m ml/s 0,082 0,022 0,081 <0,001 
C_E1 ml/s 0,064 0,020 0,064 <0,001 
C_Na* ml/s 0,058 0,019 0,055 <0,001 
CFT.O ml/s -0,041 0,018 -0,040 <0,001 
EWC ml/s -0,023 0,017 -0,02 <0,001 
F E O s m 0,041 0,012 0,038 <0,001 
F E N a " 0,029 0,011 0,029 <0,001 
FE K+ 0,129 0,061 0,113 <0,0Q 1 
FEJ-1,0 0,021 0,008 0,02! 0,164 
CVP torr 6,9 2,9 8 
Fluid intake ml/day 3743,2 899,7 3710,0 
Infusion ml/day 2147,0 821,4 2100,0 
Sodium intake mmol/day 515,9 225,5 486,0 
Sodium intake mmol/kg/ day 7,3 3,4 6,1 
Fluid output ml/day 3737,3 1156,2 3620,0 
Diuresis ml/day 3676,5 1125,7 3580,0 
Fluid balance - negative nil/day 639,1 (N=42) 503,6 502,5 
Fluid balance - positive ml/day 607,4 (N=45) 530,7 440,0 
SD - standard deviation, p-vahie - statistical significance with respect to the reference range, N — all days. 
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Table 21. Characteristics of hyponatraemia with serum sodium below 130 mmol/f. 
Parameter / ' : S_Na
+ 
< 130 mmol/1 
S Na*; 
130 -134 mul/l. p-value.-.. 
Stay in NNICU day 13,4± 10,1 9,5 ± 9,6 0,003 
Cerebral com pi i cations pts 26 (56,5%) 79 (39,7%) 0,039 
Focal pts 15(57,7%) 57 (72,2%) 0,175 
Diffuse pts 17(65,4%) 49 (62,0%) 0,758 
GCS i 3,4 i 2,4 13,3 ± 3,1 0,649 
GOS 3,8 ± 1,1 3,8 ± 1,1 0,725 
Mortality in NNICU pts 3 (6,5%) 12(6,0%) 0,901 
Days of dysnatraemia day 5,0 ±2 ,8 2,2 ±2,2 <0,001 
Osmothera]jy pts 5 (10,9%) 90 (45,2%) <0,001 
Mannitol pts 4 (80,0%) 45 (50,0%) 0,176 
Fluid intake jd l/day 3501,1 ±668 3537,4±714,5 0,824 
Infusion ml /day 1859,3 ± 611,2 1977.9 ± 711,8 0,540 
Sodium intake mmol/day 373,1 ± 184,7 411,3± 188,9 0,269 
Fluid output m l/day 3144,1 ± 1163,4 3297,2 ± 1030,2 0,404 
Diuresis jnl/day 3125,4± 1177,7 3219,6 ±1028,9 0,612 
Mean ± standard deviation, p-value -statistical significance between those groups. 
Hypernatraemia 
From 133 patients with hypernatraemia, cDI was found in 16 patients (27 days). We 
classified 118 patients as "non-cDI" (349 days), (table 22). Five patients had both types of 
hypernatraemia. The remaining patients were not evaluated because they had no serum 
osmolality measurements. 
Hypernatraemia with serum sodium above 156 mmol and 160 mmol 
Of the 133 patients with hypernatraemia, 61 (46%) had serum sodium above 156 and 34 
had serum sodium above 160. Significant differences were found in duration of hypernatraemia, 
GCS upon onset of the dysbalance and GOS between these extreme groups and other 
hypernatraemias. However, no significant differences were found between the two extreme 
groups (table 23). 
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Table 22. Characteristics of hypernatraemia in the prospective study. 
i 'Eajiyueier 1 1-1)1 ; ' : non c p r jpjS; : p-vallic 
Number of patients pts 16(100,0%) 118(100,0%) 
Male pts 4 (25,0%) 56 (47,5%) 0,166 
Age years 48,9 ±17,8 61,6± 13,6 0,009 
Stay in NNICU day 7,9 ±6 ,9 13,3 ± 10,8 0,014 
NYHA 1,3 ±0 ,6 1,5 ±0,7 0,527 
Stroke pts 10(62,5%) 79 (66,9%) 0,809 
Tumour pts 3(18,8%) 15(12,7%) 0,247 
Trauma pts 2(12,5%) 18(15,3%) 0,572 
Operation pts 11 (68,8%) 101 (85,6%) 0,085 
Days after operation day 2,5 ±2,3 5,1 ±8 ,4 0,145 
Cerebral complications pts 14(87,5%) 94 (79,7%) 0,E09 
Pulmonary oedema pts 0 (0,0%) 13(11,0%) 0,110 
COS 1,6 ± 1,3 2,5 ± 1,2 0,079 
Mortality in NNICU pts 12(75,0%) 34 (28,8%) 0,012 
Days of dysnatraemia day 27(100,0%) 349(100,0%) 
S Na' mmol/l 160,1 ±8,4 154,4 ±3,4 <0,001 
S Na+ 151 - 155 mmol/l 153,0± 1,2(N= 11) 152,5±1,3(N=2<19) 0,246 
S Na+ 156-160 mmol/1 157,0±1,4{N=4) 157,6±1,3(N~7I) 0,405 
S_Nn+ >160 mmOl/1 167,6±7,1(N-12) 162,3±1,7(N=29) 0,001 
Lenght of dysnatraemia day 3,3 ±2,1 3,4 ± 2,3 0,139 
GCS 6,8 ±5,1 9,6 ±4,1 0,192 
Admission in NNICU pts 2(12,5%) 6(5,1%) 0,158 
Osmotherapy pts 13(81,3%) 102(86,4%) 0,221 
Mannitol pis 5 (38,5%) 40 (39,2%) 0,925 
NaCl10% pts 11 (84,6%) 93(91,2%) 0,219 
Diuretics pts 5(18,5%) 179(51,3%) 0,001 
Furoscmid pis 4 (8D,0%) 154 (86%) 0,716 
CVP torr 6,2 ±2,8 5,2 ±4,1 0,441 
Fluid intake ml/day 4306,7 ± 1251,6 3683,5 ±741,9 <0,001 
Infusion ml/day 3634,8 ± 1291,8 2435,1 ± 950,0 <0,001 
Sodium intake mmol/day 462,7 ±215,2 422,4 ± 187,7 0,327 
Sodium intake mmol/kg/day 6,0 ±3 ,0 5,7 ±2,8 0,663 
Fluid output ml/day 5030,7 ±2198,7 2872,8 ±971,1 <0,001 
Diuresis ml/day 5195,9 ±2134,2 2624,9 ±929,0 <0,001 
Fluid balance - negative day 17(63,0%) 47(13,5%) <0,001 
S O s m mmol/kg 329,3 ± 16,2 322,3 ± 13,3 0,027 
S OsmC mmol/kg 333,8 ± 17,7 325,8 ± 9,9) 0,043 
U Osm mmol/kg 436 ± 256,9 608,5 ± 174,6 <0:001 
S K+ mmol/l 4,0 ±0,4 3.9 ± 0,5 0,229 
S_Glu mmol/l 6,8 ± 1,7 6,1 ±1,6 0,029 
S Urea mmol/l 6,0 ±3,5 10,7 ±6 ,7 <0,001 
S Cr umol/1 99,9 ±26,9 117,8 ±88,5 0,614 
dU Na+ mmol/day 437,4± 181,5 369,7 ± 185,9 0,198 
dU Na7dU K+ 4,1± 1,7 3,7 ±2 ,3 0,412 
C_Cr ml/s 1,7 ±0 ,4 1,7 ±0,4 0,472 
C Osm ml/s 0,061 ±0,019 0,060 ±0,017 0,823 
C El ml/s 0,039 ±0,014 0,035 ±0,015 0,311 
C Na+ ml/s 0,031 ±0,013 0,028 ±0,014 0,340 
C H 20 mi/s -0,007 ±0,016 -0,028 ±0,012 <0,001 
EWC ml/s 0,016 ±0,014 -0,003 ±0,0 ID <0,001 
FE Osm 0,036 ±0,008 0,035 ±0,009 0,637 
FE Na" 0,019 ±0,006 0,016 ±0,008 0,212 
FE U20 0,034 ±0,009 0,019 ±0,006 <0,001 
Mean ± standard deviation, p-value -statistical significance between these groups, N — all days, p-value 
is without 5 pis, who had both DI and non cDI. 
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Table 23. Comparison of hypernatraemia with serum sodium above 156 mmol/l and 160 mmol/l. 
. , ; : Parameter S i ': . . . S_Na' J S p g > 156 mmol/i: 
: SJS'a"? 
) ' > I60"mmiíl/I p-va|Be 
Number of patients pts 61 (100,0%) 34 (100,0%) 
Slay in NNICU day 12,5 ± 11.3 11,6 ± 9,9 0,825 
Length of dysnatraemia day 4,3 ± 2,4 4,4 ±2 ,6 0,853 
GCS 8,1 ±4 ,4 7,8 ±4 ,4 0,743 
GOS 2,0 ± 1,2 1,9 ±1 ,2 0,718 
Mortality in NNTCU pts 28 (45,9%) 18 (52,9%) 0,510 
Mean ± standard deviation, p-value—statistical significance between these groups. 
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NT-proBNP in acute brain diseases 
Significantly higher mean serum values of NT-proBNP were found in patients with 
hyponalracmia (379,3 ± 490,2 pg/ml) compared to the given reference level (125 pg/ml, p < 
0,001). 
However, significantly higher values were also found in the control group (268,3 ± 203,9 
pg/ml, p = 0,005), i.e. in patients with acute brain disease, normonatraemia, nonnoosmolality 
and who were classified .NYH A I. 
There were no significant differences found either while comparing hypoosmolal and 
normoosmolal Jiyponatraeinias in patients with NYHA I (p - 0,933), or comparing hypoosmolal 
and normoosmolal hyponatremias with the control group (p = 0,776). 
In patients with CSW and NYHA I. serum sodium values were significantly higher than 
those of the control group (p < 0,001), (table 24). The mean value was 430,4 ± 706,4 pg/ml (p = 
0,001). The relationship between NT-proBNP and the measured parameters in patients with 
CSW and normonatraemia can be seen in table 25. No patient with CSW had pulmonary oedema 
during the course of their hospitalisation. 
Table 24. Comparison of serum NT-proBNP and other parameters in CSW and in patients with 
normonatraemia in acutc brain diseases and NYHA 1. 
Parameter • . CSW NVHA 1. ' 
Noruioiiairaeinia 
NYHA I. . • p-yátuě v; 
NT-proBNP pg/ml 430,4 ± 706,4 268,3 ± 203,9 <0,001 
Number of patients pts 19(100,0%) 20(100,0%) 
Age years <14,9 ±16,3 51,7 ± 12,9 0,267 
S_Na* minol/J J 29,3 ± 3,6 139,7 ±3,6 0,292 
S O s r o nimol/kg 271,6 ±9 ,7 287,3 ±4 ,0 <0,001 
S O s m C mmol/kg 268,4 ± 8,9 289,2 ± 7,0 0,295 
U O s m mmol/kg 663,0 ± 169,2 667,5 ± 177,1 0,000 
U Osni/S Osm 2,4 ± 0,6 2,3 ±0,6 0,938 
C Cr 2,2 ± 0,4 2,1 ±0,6 0,681 
dU_Na+ mmol/day 682,4± 216 548,0 ± 163,9 0,036 
dUJČ mmol/day 95,6 ±41,1 78,7 ± 29,4 0,150 
dlJ Na' /dU_K+ 8,7 ± 6,4 7,9 ± 3,9 0,930 
C Osm ml/s 0,087 ± 0,023 0,079 ± 0,032 0,373 
C_E1 ml/s 0,070 ±0,021 0,050 ± 0,013 0,001 
C_Na+ ml/s 0,061 ±0,019 D,045± 0,014 0,007 
C H 20 ml/s -0,047 ±0,019 -0,042 ± 0,023 0,503 
EWC ml/s -0,030 ±0,018 -0,013 ±0,009 0,001 
F E O s m 0,040 ± 0,008 0,038 ±0,015 0,566 
FENa* 0,029 ±0,01 0,022 i 0,010 0,059 
F E J N O 0,019± 0,005 0,018±0,006 0,713 
Fluid intake ml/day 3606,5 ±821,8 3453,0 ±567,7 0,440 
Sodium intake mmol/day 589,4 ±258,4 433,5 ±133,4 0,508 
Sodium intake mmol/kg/ day 8,4 ±4,1 5,8 ±2,1 0,024 
Fluid output ml/day 3627,6± 1132,1 3222,4 ± 959,7 0,317 
Diuresis ml/day 3538,2± 1052,8 3199,0 ± 976,8 0,019 
Mean J. standard deviation, p-value -statistical significance between these groups. 
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Table 25. The relationship between NT-proBNP and the observed parameters in patients 
with CSW and nonuonatraemia in acutc brain disease and NYHA I. 
Correlation with JVT-pro BNP 
• Parameter - Rs (p-v 
CSW 
iitue) . . . 
Normonatraeraia 
(N=19) (N=20) 
CCS -0,207 (p=0,394) -0,240 (p-0,308 
S„Na+ -0,521 (p=0,022) 0,300 (p=0,199) 
S O s m -0,259 (p=0,284) 0,339 (p=0,144) 
S O s m C -0,317 (p=0,186) 0,298 (p =0,202) 
U O s m -0,004 (p=0,989) -0,159 (p=0,515) 
U_Osm/S_Osm -0,030 (p=0.906) -0,179 (p=0,464) 
S U r e a -0,323 (p=0,177) -0,204 (p=0,394) 
S C r -0,067 (p=0,784) -0,130 (p=0,582) 
dlf_N;V -0,462 (p=0,054) -0,063 (p=0,792) 
dU Na7dU_K ř -0,011 (p=0,964) -0,231 (p=0,327) 
C Osm -0,510{p=0,031) -0,248 (p=0,292) 
C_EI -0,474 (p=0,047) -0,119 (p=0,62f) 
C J i a 1 -0,453 (p=0,059) -0,089 (p=0.708) 
C_H20 0,466 {(1=0,051) 0,227 (p=0,335) 
C E W C 0,389 {p=0,l 11) -0,091 (p=0,702) 
F E O s m -0,332 (p=0,178) 0,129 (p=0,587) 
FE_Na+ -0,230 (p=0,359) 0,293 (p=0,211) 
FE^HjO 0,100 (p=0,694) 0,332 (p=0,f 79) 
Fluid intake -0,488 (p=0,047) -0,090 (p=0,707) 
Sodium intake (mmol/day) -0,243 (p=0,348) -0,001 (p=0,995) 
Sodium intake (mmol/day/kg) -0,147 (p=0,573) 0,058 (p=0,809) 
Fluid output -0,201 (p=0,439) -0,193 (p=0,414) 
Diuresis -0,216 (p=0,406) -0,202 (p=0,392) 
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Discussion 
The results of our study showed that dysnatraemia is a frequent dysbalance of effective 
osmolality in acute brain diseases [1-8]. In the prospective sludy, which was carried out along 
with the systematic database NNICU, acute dysnatraemia occurred in 24% of patients admitted 
lo our NNTCU. These results show that it is necessary to pay attention to and actively search for 
sodium dysbalances in neurointensive care. The daily monitoring of serum sodium should be a 
matter of course in all aci'ite brain diseases. 
The overall incidence of dysbalances in the prospective study slightly increased, from 
326 to 378 patients. This rise was in hypematraemia (1,7 x), which was connected with the 
introduction of two beds with a ventilation facility in 2003, which led lo the admittance of 
patients with serious brain diseases. The mean value of GCS upon onset of hypernalraemia was 
12 ± 3,4, compared to the prospective sludy, where it was 9,4 ± 4,3. The new equipment also led 
lo a rise in hyponalraemia, which had been stable in previous years. 
The most frequent diagnosis in both groups in our study was stroke, then brain tumours 
and trauma. This is because our NNICU focuses more on strokes and tumours than trauma. The 
majority of patients in our study had operations, which is also in keeping with the character of 
our NNTCU, which admils more neurosurgical than neurological patients. No differences were 
found between the onset of dysnatraemia and brain damage in the retrospective study, in contrast 
to the prospective study, where hypematraemia arose significantly earlier (p < 0,001). 
In accordance with literature [1], in both the retrospective (77 %) and the prospective (65 
%) stndy the majority of patients had hyponatraemia, but hypernalraemia was prognostically 
more serious. Hypematraemia was connected with more cerebral complications, worse GOS, and 
higher mortality in the NNTCU, but it arose with significantly lower GCS. Meanwhile, the 
incidence of these dysbalances was not different for focal and diffuse brain lesions. These 
findings were the same in the relrospcclive and prospective studies. In the prospective study, 
where we observed change of consciousness during the onset of dysnatraemia, hypematraemia 
was related to worsening consciousness (p < 0,001), in hyponatraemia consciousness did not 
change (p < 0,001), and in neither group did consciousness improve (p = 0,235). Similar changes 
were found in brain CT, progress was observed in hypematraemia, as was regression, but only 
110 of the patients had this examination. No changes were found in either of the dysbalances. In 
the prospective study, not only did we evaluate the the overall incidence of difiise complications 
but their individual components too. We did not find differences between dysnatraemias in 
incidence of vasospasms (p = 0,572) and hydrocephalus (p = 0,232) but difiise brain oedema was 
significantly higher in hypematraemia (p = 0,001). Our results therefore support the theory of the 
onset of hypematraemia and severity of brain disease within the framework of compensatory 
regulation in the organism. 
During the observation of further parameters among dysnatraemias, significant 
differences were not found in the length of dysnatraemia, but in its presence upon admission to 
the NNICU. Hyponatraemia was more common, and was found more often in the prospective 
sludy (134, 54,7 %) than in the retrospective (101, 40,2 %). The reason for this was 
hyperglycaemia, mannitol and increased urea, and less frequently the use of diuretics. 
In acute brain disease, acute dysnatraemias prevail. The prospective study showed that 
hypematraemia was acute in 98,5 % of patients. We found that hyponatraemia was acute in 
about 62,9 % of patients, but we did not evaluate the onset in all cases because in 33,9 % of 
patients the dysbalance was discovered in the admission blood test. Six of these patients received 
mannitol. 
In literature, it is known that antioedematic therapy leads to dysnatraemia [6, 70]. Tn both 
our retrospective (p = 0,001) and prospective (p < 0,001) study antioedematic therapy most often 
led to hypematraemia. Regarding use of hypertonic saline, there were no differences between 
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these dysbalances in sodium intake. Diuretics were more frequent in hypematraemia, but only in 
the prospective study (p < 0,001). In 94,8 % of case, furosemide was given. 
These dysbalances had no influence on CVP (p = 0,684). This parameter, however, was 
measured only in the prospective study. In the period of retrospective study, especially at the 
beginning, it was not a routine monitoring method in our NNICU. 
Tn our experience it is possible to cany out differential diagnostics of hyponatraemia only 
when measured and calculated renal function parameters arc available, in contrast to 
hypematraemia, where complete cDl can be diagnosed without these parameters. 
Hyponatraemia 
Hyponatraemia is a serious complication in the NNICU when it is connected to low 
effective osmolality, i.e. with serum hypoosmolality [7]. Therefore, in the first phase of our study 
we divided hyponatremias into three groups according to measured serum osmolality. The 
results of both parts of our study showed that hyponatraemia with hypoosmolality is not a 
frequent type of hyponatraemia. In the retrospective study, there were 50 (20 %) cases and in the 
prospective (22 %) study there were 55. Regarding the total number of hyponatremias, there 
was an almost equal incidence of this dysbalance. Even though scrum osmolality was not 
measured in all hyponatremias, more were found in the retrospective study. Measured 
osmolality was mostly missing in hyponatraemia lasting one day. Due to the amount of mannitol 
use, we did not apply calculated serum osmolality for dividing the hyponatremias. 
The majority of hyponatremias had measured serum osmolality within the reference 
ranges. Fewer hyponatremias occurred with serum hyperosmolality. These hyperosmolal 
hyponatraemias did not last long: their mean duration in the retrospective study was 1,1 ± 0,2 
days, in the prospective 1,2 ± 0,5 days. The reason for normoosmolal and hyperosmolal 
hyponatraemia can be seen first of all in hyperglycaemia, high levels of urea or mannitol 
osmotherapy. The highest mean values of glycaemia and urea in serum were found in 
hyperosmolal hyponatraemia, followed by normoosmolal, and finally hypoosmolal 
hyponatraemia. These differences were significant in both the retrospective and prospective 
studies. 
Regarding the possibility of a brain oedema arising, it is necessary to pay special 
attention to hypoosmolal hyponatremia. Timely and accurate diagnosis is essential. We consider 
measured and calculated renal function parameters to be a relatively simple method, with the 
further advantage of being accessible in daily clinical practice. 
In neurointensive care hypoosmolal hyponatremia is connected to two differenl 
syndromes - the more frequent CSW and less common STADH [34], as was also seen in our 
study. We did not have one case of SfADH in either the retrospective or the prospective study. 
Diagnostics were not carried out in all patients with hypoosmolal hyponatraemia, due to not 
having renal function parameters for these patients. There were 21 patients in the retrospective 
study and 27 in the prospective study. This is a relatively high count in the prospective study, but 
18 of them had one-day hyposmolal hyponatraemia, which was discovered upon entry to the 
NNTCU in 12 cases. The other 6 patients had hyponatraemia lasting two days. 
During evaluation of renal function parameters in diagnosis of dysnatraemia it is 
important in every case lo distinguish its cause from the organism's compensatory response, 
which means correctly identifying the ADH-kidney axis [16]. In the case of normonatraeinia 
with polyuria with low specific urine weight and positive EWC, if we prescribe desmopressin 
then hyponatraemia can arise due to free water retention. This situation came about in 4 patients 
in the retrospective study and one in the prospective study. There was no hyponatraemia caused 
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by hypotonic solution in the retrospective study, and one case in the prospective study. From our 
results it can be seen that the prevalent hypoosmolal hyponatraemia in acute brain disease is 
CSW. We had 51 such patients in our 10 year retrospective study. We found this figure 
surprisingly low and we incline towards Singh's opinion (2002) that CSW probably occurs less 
frequently than is supposed in literature [51]. Even though differential diagnosis was not carried 
out in all hypoosmolal hyponatraemias, in our experience CSW is not seen in hyponatraemia 
lasting only one- or two-days. 
The assessment of the hormones which participate in the cause of these two syndromes is 
not bencficial with regards to the compensatory changcs to the fluid volume [8]. In SIADH, free 
water retention leads to volume expansion and following stimulation of natriuretic peptides. Tn 
CSW it is the other way around, the primary rise in NP leads to content depletion and a 
secondary increase in ADÍI levels. Furthermore, only NP assessment is acccssible in practice, 
especially NT-proBNP. 
Differential diagnosis is essential because different mechanisms require different 
therapies [39]. In CSW [7, 53] sodium and fluids are substituted, in SIADH [51] fluids are 
restricted and diuretics applied. In SAH with vasospasms it is even dangerous to carry out fluid 
restriction [47]. Renal function parameters therefore are of benefit in diagnosing hyponatraemia 
[8]. According to basic laboratory parameters (serum sodium, measured serum osmolality and 
ratio urine and serum osmolality) it is impossible to carry out diagnosis, because CSW and 
SIADH are the same. Assessment of renal function parameters has even led to the rc-evaluating 
the original diagnosis of SIADI-1 as CSW [10]. 
During comparisons of individual groups according to measured serum osmolality it was 
found that there were significantly more cerebral complications in hypoosmolal hyponatraemia, 
but without any influence on the outcome of these patients. These findings were in both parts of 
the study. Neither did we discover significant changes of consciousness and brain CT. When we 
compared sodium intake in these three groups, we also did not find any differences. 
During hyponatraemia therapy, we must always bear in mind the rule of sodium 
correction. In a fast rise there is a risk of pontine and extrapontine myelinolysis [58-63], First, we 
need to find out whether the hyponatraemia is acute or chronic [63]. Next, we have to set the 
target value of sodium in 24 hours. To prevent this complication, it is important to take at least 
four serum sodium samples per day (6 hours interval), which was why we included this rule in 
our prospective protocol. However, in some cases we had to take more samples. Tn our 10-year 
study we did not have this complication, even though three patients exceeded tlie safety range of 
sodium shift, with 16, 20 and 22 minol/24 hours. The mean increase in serum sodium was 4,9 ± 
3,8 mmol/1, in the retrospective study and 5,5 ± 4,7 mmol/1 in the prospective study. To prevent 
late discovery of hyponatraemia, we carry out serum sodium testing every day on patients with 
acutc brain diseases. 
If we do not find the typical syndromes accompanying acute brain disease, CSW and 
SIADH, we need to look for other causes of hyponatraemia [57]. Hypocorticalism, 
hypoaldosteronism, polydypsia in chronic alcoholism or iatrogenic, and especially unindicated 
administration of desmopressin all appeared in our study. In these cases we also find renal 
function parameters useful, especially EWC [16]. 
Patient numbers with extreme hyponatraemia with serum sodium levels below 130 
mmol/1 were almost the same in the retrospective (21 %) and prospective ( 19 %) studies. There 
were, however, differences in the duration of the dysbalance (106 days in the retrospective study 
and 66 days in the prospective study. In comparison with this extreme group, other 
hyponatraemias lasted significantly longer and had more cerebral complications, although with 
no negative influence on the outcomes of the patients. These results were the same in both 
studies. 
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Hypernatraemia 
Hypernatraemia occurs less frequently in acute brain disease than hyponatraemia, but is 
prognostically more serious [1], Tt is therefore necessary to pay it greater attention. With regards 
to its seriousness, it is important not only to timely and accurately diagnose the dysbalance but 
also precisely set target serum sodium values to be achieved. All hypernatraemias with 
hyperosmolality cause hypertonicity ECT to shift water from the brain cells to ECT, thereby 
leading a decrease of intracranial pressure. 
Typical hypernatraemia connected to acute brain disease is known as central diabetes 
insipidus [66]. Nowadays, however, it is not a frequent hypernatraemia in neurointensive care 
[6]. In our 10-year study we only had 24 patients with cDI, 8 of whom were in the retrospective 
study. More were in the prospective study, also with higher mortality (75% to 25%), which was 
related to the introduction of (wo beds with ventilation in Our NNICU in 2003. 
In none of our patients did we observe the illness' three-phase process as described in 
literature [8], in our view because of precise doses of desmopressin according to hourly diuresis, 
specific gravity of urine and osmolality of urine, and especially due to EWC. The antidiuretic 
phase, following the diuretic phase, is less down to release of previously synthesized ADH as to 
degenerating hypofysis, casuscd by continuing regular desmopressin therapy. 
Central diabetes insipidus generally arises from pressure built up around the hypofysis 
and hypothalamus. It can be in local lesions, for example adenoms, base skull fractures etc, or in 
diffuse brain lesions with intracranial hypertension which are so large that they cause pressure in 
this area [8]. Antioedematic therapy is used to lower intracranial pressure in patients with severly 
worsening brain damage. In these cases, when we prescribe hypertonic saline, daily sodium 
intake persists during the onset of cDI, then EWC is diagnostically beneficial. In our evaluation, 
renal function parameters differed significantly between cDI and "non cDI" groups in EWC (p < 
0,001), C_H20 (p < 0,001) a FE H20 (p < 0,001). 
This dysnatraemia has one advantage compared to others, in that casual desmopressin 
therapy is available. Tn neurointensive care we prefer intravenous administration to nasal, as it is 
more exact. Nowadays Octostim is only available by extraordinary import. 
In neurointensive care the most frequently occurring hypernatraemia is not cDI but that 
with multifactorial causes [6]. For simplification and better orientation in this field we have 
termed these hypernatraemias "non cDT." This name has also been accepted in daily clinical 
practice. There were 59 patients in this group in the retrospective study, and 118 patients in the 
prospective study, a considerably higher number. Five patients had botli types of hypernatraemia. 
Aiyagari Venkatesh [6] wrote of the higher incidence of renal failure in hypernatraemia 
in his studies. In our study, there was one patient in the retrospective study and 20 in the 
prospective study with this illness. 
Antioedematic therapy is a frequent cause of the onset of "non cDI" hypernatraemia. 
During the 10-year study, (his therapy changed considerably. In the retrospective study, mannitol 
was usus ally given (81 % pts), whereas in the prospective study only 39 % of patients received 
it. In this period we started using hypertonic saline. This change had an influence, in that there 
was no difference in daily intake of sodium between cDI and "non cDI" groups. 
Comparing cDI and "non cDT" by outcome, there were no significant changes in mean 
value in GOS (p = 0,079), but NNICU mortality was higher in cDI (p = 0,012). 
Hypernatraemias with serum sadim above 156 mmol/1 and 160 minol/l were more serious 
in both parts of the study. These extreme hypernatraemias, in comparison with others, had 
significantly lower GOS and higher NNICU mortality, but differences between the two extreme 
groups were not found. 
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NT-proBNP in acute brain diseases 
Natriuretic peptides are mostly used in cardiology, where their usefulness as biochemical 
markers of heart failure [31] and prognostic significance [32] are well known. Assesment of 
these NP in neurointensive care lags behind cardiologists, although studies have been published 
on the relationship between natriuretic peptides and acute brain diseases [33-36], especially in 
hyponatraemia with natriuresis in CSW [33, 34]. 
The cause of raised natriuretic peptide levels in brain disease is still unclear, but both 
cerebral and cardiac etliiology are under consideration. It is thought that the origin could be 
related to the heart because the expression of these peptides is far higher in the myocardium than 
the brain [35] and because the concentration of natriuretic peptides is higher in serum than in 
cerebrospinal fluid. 
The possible influence of hypervolemia or a neurogcnnic lung oedema in SAH has also 
been considered. When intracranial pressure is raised, the patient's ANP and BNP serum levels 
also rise, which leads to the logical assumption that raising natriuretic peptides constitutes an 
adaptational response to raised intracranial pressure and brain oedema [35]. 
In our collection, we found patients with CSW to have significantly higher NT-proBNP 
levels compared not only to the reference range (p = 0,001), but also to the control group (p < 
0,001). There were no differences in fluid intake (p = 0,440) between the two groups, but there 
were in sodium intake per kg body weight (p = 0,024) and diuresis (p = 0,019). Patients with 
CSW had high daily sodium output (p = 0,036), C E1 (p = 0,001) and C_Na+ (p = 0,007). Our 
results showed that natriuresis widi hypoosmolal hyponatraemia in CSW was related to high 
serum levels of NT-proBNP. Further analysis of the control group did not show any relationship 
between NT-proBNP and measured parameters, in contrast to CSW, where we found a negative 
relation between NT-proBNP and serum sodium, C Osm, C_EI and fluid intake. Only patients 
with NYHA T. and physiological renal parameters were assessed in our study in order to preclude 
possible influence by high levels of NT-proBNP. We tried to obtain precise NYHA classification 
evaluations. We made use of results from cardiological, medical and anaesthesiological 
examinations. No patient with CSW had pulmonary oedema. 
However, significantly high serum levels of NT-proBNP compared to the reference value 
were found in normoosmolal hyponatraemia and also in the control group, i.e. in patients with 
acute brain disease, normonatraemia, serum normoosmolality and without heart disease with 
NYHA I. From these results we can deduce that the spectrum of causes of NP is much more 
complex. On the basis of studies published until now and regarding the presence of BNP in the 
brain [30], we suppose that acute brain disease could be another field of its use. In this way 
neurointensive care can become another possible area for research of NT-proBNP as a 
prognostic marker and thereby broaden the perspectives of its function. 
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Conclusions 
1. Dysbalanccs of effective osmolality are some of the most frequent and serious 
complications in neurointensive care. It is necessary to pay attention to and actively 
search for them. Daily monitoring of serum sodium should be part of the daily care of 
cvciy patient with acute brain disease. 
2. Hyponatraemia is more common than hypernatraemia, but hypernatraemia is 
prognostically worse. 
3. Hyponatraemia with low effective osmolality is not a frequent type of hyponatraemia in 
neurointensive care. The prevalent hyponatraemia had scrum osmolality within the 
reference range. 
4. Typical hypoosmolal hyponatraemia in acute brain disease is ccrebral salt wasting (CSW) 
syndrome, in contrast to syndrome of inappropriate secretion of antidiuretic hormone 
(SIADH), which was not found in our ten-year study. Hypoosmolal hyponatraemia can 
also arise from other reasons, for example due to iatrogenic Causes. 
5. In neurointensive care central diabetes insipidus (cDl) is not the most common type of 
hypernatraemia. Most hypernatraemias have multifactorial causes (due to antieoedeinatic 
therapy, renal failure). In daily clinical practice the term "non cDl' is useful to describe 
these hypernatraemias remaining after separating cDl. 
6. Timely and accurate diagnosis of dysnatraemia in acute brain diseases is due to the 
seriousness essential. Nowadays this is easily achieved through measuring and 
calculating renal function parameters, which had the further advantage of being 
accessible in daily clinical practice. The most important parameter is electrolyte free 
water clearance (EWC). 
7. Tn our experience it is possible to carry out differential diagnostics of hyponatraemia only 
when measured and calculated renal function parameters are available, in contrast to 
hypernatraemia, where complete cDl can be diagnosed without these parameters. 
8. Implementation of renal function parameters in clinical practice ought to be carried out in 
all places where patients with acute brain diseases are treated. 
9. In order to prevent the onset of pontine and extrapontinc myelinolysis, the 
recommendations for the proper correction of natraemia must be kept, i.e. do not exceed 
the planned target levels of serum sodium. We consider 6 hours to be the minimal 
interval for chccking the serum sodium levels. 
10. Natl 'iuresis with hypoosmolal hyponatraemia in CSW was related to high scrum levels of 
NT-proBNP. 
11. The assessment of NT-proBNP in the brain and the finding of raised NT-proBNP values 
in patients with acute brain disease and normonatraemia in neurointensive care could be 
the subject for further research. 
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Summary 
Tntrodaction: Dysbalances of effective osmolality arc some of the most frequent and serious 
complications in neurointensive care. Their severity lies in brain oedema in hyponatraemia and 
dehydration of the brain in hypernatraemia. Due to the seriousness of dysnatraemia in acute brain 
diseases, timely and accurate diagnosis is necessary. Nowadays this is easily achieved through 
measuring and calculating renal function parameters. 
The aims of this study were 1) evaluation of hyponatraemia and hypernatraemia in acute brain 
diseases after establishing these renal parameters into clinical practice in our NNICU and 2) 
determining the significance ofNT-proBNP in differential diagnostics of hyponatraemia. 
Methods: Over a ten-year period, in a retrospective (1.1.1996 - 31.12.2000) and a prospective 
study (1.1.2001 - 31.12.2005) we evaluated all patients hospitalised in our NNICU with acute 
brain diseases, who had scrum sodium below 135 mmol/1 (collection hyponatraemia) or above 
150 mmol/1 (collection hypernatraemia). The prospective part took place according to standard 
protocol for diagnosing hyponatraemia and hypernatraemia in the NNICU, which includes the 
measuring and calculating of renal function parameters. In the prospective study, assesment of 
NT-proBNP was carricd out on 40 patients with hyponatraemia. The control group consisted of 
20 patients with acute brain disease and normonatraemia. 
Results: 
Table 1. Overview of dysnatraemias in patients with acute brain diseases. 
Retrospeetive.stúdy jťiqspícťive study 
Dysnatraemia pts 326 (100,0%) 378(100%) 
Hyponatraemia pis 251 (77%) 245 (65%) 
Hypernatraemia pts 75 (23%) 133 (35%) 
Hyponatraemia pts 
Hypoosmolal pts 50 55 
Normoosmolal pts 154 184 
Hyperosmolal pts 38 45 
CSW pts 25 26 
SIADH pts 0 0 
cDI pts 8 16 
Non cDI pts 59 118 
CSW - cerebral salt wasting, S1ADH - syndrome of inappropriate secretion of 
antidiuretic hormone, cDI - central diabetes insipidus, non cDT - hypernatraemia 
non central diabetes insipidus, NB. Not all natraemias had measured serum 
osmolality, and some patients had more types of dysnatraemia during stay in 
NNICU. 
Table 2. Serum levels of NT-proBNP in CSW and normonatraemia 
in patients with acute brain diseases and NYHA I. 
.Parameter 1 --*" ' CS\V:V iSQrmóngtrňemiá; value™ 
NT-proBNP | pg/ml 430,4 ±706,4 268,3 ± 203,9 < 0,001 
Mean ± standard deviation. 
Conclusion: Measured and calculated renal function parameters represent an easy and 
accessible method in differential diagnostics of hyponatraemia and hypernatraemia in patients in 
neurointensive care. Differential diagnostics of hyponatraemia cannot be carried out without 
them, whereas in hypernatraemia where there is complete cDI it is possible. Due to the 
seriousness of dysnatraemia in acute brain diseases, their implementation in clinical practice 
ought to be a matter of course in all places where patients with acute brain diseases are treated. 
Natriuresis with hypoosmolal hyponatraemia in CSW was related to high scrum levels of NT-
proBNP. 
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